

# **PHILIPPINE BIDDING DOCUMENTS**

for the

## **Supply and Delivery of Various Drugs and Medicines – Ampules and Vials Resale for CY 2023 Framework Agreement**

**Project Reference No.: BAC1-2022-11-0077-A**

**End-User: Property and Supply Division,  
Philippine General Hospital**

**UPM – PHILIPPINE GENERAL HOSPITAL**

# Preface

These Philippine Bidding Documents (PBDs) for the procurement of Goods through Competitive Bidding have been prepared by the Government of the Philippines for use by any branch, constitutional commission or office, agency, department, bureau, office, or instrumentality of the Government of the Philippines, National Government Agencies, including Government-Owned and/or Controlled Corporations, Government Financing Institutions, State Universities and Colleges, and Local Government Unit. The procedures and practices presented in this document have been developed through broad experience, and are for mandatory use in projects that are financed in whole or in part by the Government of the Philippines or any foreign government/foreign or international financing institution in accordance with the provisions of the 2016 revised Implementing Rules and Regulations of Republic Act No. 9184.

The Bidding Documents shall clearly and adequately define, among others: (i) the objectives, scope, and expected outputs and/or results of the proposed contract or Framework Agreement, as the case may be; (ii) the eligibility requirements of Bidders; (iii) the expected contract or Framework Agreement duration, the estimated quantity in the case of procurement of goods, delivery schedule and/or time frame; and (iv) the obligations, duties, and/or functions of the winning bidder.

Care should be taken to check the relevance of the provisions of the PBDs against the requirements of the specific Goods to be procured. If duplication of a subject is inevitable in other sections of the document prepared by the Procuring Entity, care must be exercised to avoid contradictions between clauses dealing with the same matter.

Moreover, each section is prepared with notes intended only as information for the Procuring Entity or the person drafting the Bidding Documents. They shall not be included in the final documents. The following general directions should be observed when using the documents:

- a. All the documents listed in the Table of Contents are normally required for the procurement of Goods. However, they should be adapted as necessary to the circumstances of the particular Procurement Project.
- b. Specific details, such as the “*name of the Procuring Entity*” and “*address for bid submission*,” should be furnished in the Instructions to Bidders, Bid Data Sheet, and Special Conditions of Contract. The final documents should contain neither blank spaces nor options.
- c. This Preface and the footnotes or notes in italics included in the Invitation to Bid, Bid Data Sheet, General Conditions of Contract, Special Conditions of Contract, Schedule of Requirements, and Specifications are not part of the text of the final document, although they contain instructions that the Procuring Entity should strictly follow.

- d. The cover should be modified as required to identify the Bidding Documents as to the Procurement Project, Project Identification Number, and Procuring Entity, in addition to the date of issue.
- e. Modifications for specific Procurement Project details should be provided in the Special Conditions of Contract as amendments to the Conditions of Contract. For easy completion, whenever reference has to be made to specific clauses in the Bid Data Sheet or Special Conditions of Contract, these terms shall be printed in bold typeface on Sections I (Instructions to Bidders) and III (General Conditions of Contract), respectively.
- f. For guidelines on the use of Bidding Forms and the procurement of Foreign-Assisted Projects, these will be covered by a separate issuance of the Government Procurement Policy Board.

# Table of Contents

<b>Glossary of Acronyms, Terms, and Abbreviations .....</b>	<b>4</b>
<b>Section I. Invitation to Bid.....</b>	<b>7</b>
<b>Section II. Instructions to Bidders.....</b>	<b>9</b>
1. Scope of Bid .....	11
2. Funding Information.....	11
3. Bidding Requirements .....	11
4. Corrupt, Fraudulent, Collusive, and Coercive Practices .....	11
5. Eligible Bidders.....	11
6. Origin of Goods .....	13
7. Subcontracts .....	13
8. Pre-Bid Conference .....	13
9. Clarification and Amendment of Bidding Documents .....	13
10. Documents comprising the Bid: Eligibility and Technical Components .....	13
11. Documents comprising the Bid: Financial Component .....	14
12. Bid Prices .....	14
13. Bid and Payment Currencies .....	15
14. Bid Security .....	15
15. Sealing and Marking of Bids .....	16
16. Deadline for Submission of Bids .....	16
17. Opening and Preliminary Examination of Bids .....	16
18. Domestic Preference .....	16
19. Detailed Evaluation and Comparison of Bids .....	17
20. Post-Qualification .....	17
21. Signing of the Contract .....	18
<b>Section III. Bid Data Sheet .....</b>	<b>19</b>
<b>Section IV. General Conditions of Contract.....</b>	<b>31</b>
1. Scope of Contract .....	32
2. Advance Payment and Terms of Payment .....	32
3. Performance Security .....	32
4. Inspection and Tests .....	33
5. Warranty .....	33
6. Liability of the Supplier .....	33
<b>Section V. Special Conditions of Contract .....</b>	<b>34</b>
<b>Section VI. Schedule of Requirements .....</b>	<b>38</b>
<b>Section VII. Technical Specifications .....</b>	<b>47</b>
<b>Section VIII. Checklist of Technical and Financial Documents .....</b>	<b>50</b>

# ***Glossary of Acronyms, Terms, and Abbreviations***

**ABC** – Approved Budget for the Contract.

**BAC** – Bids and Awards Committee.

**Bid** – A signed offer or proposal to undertake a contract submitted by a bidder in response to and in consonance with the requirements of the bidding documents. Also referred to as *Proposal* and *Tender*. (2016 revised IRR, Section 5[c])

**Bidder** – Refers to a contractor, manufacturer, supplier, distributor and/or consultant who submits a bid in response to the requirements of the Bidding Documents. (2016 revised IRR, Section 5[d])

**Bidding Documents** – The documents issued by the Procuring Entity as the bases for bids, furnishing all information necessary for a prospective bidder to prepare a bid for the Goods, Infrastructure Projects, and/or Consulting Services required by the Procuring Entity. (2016 revised IRR, Section 5[e])

**BIR** – Bureau of Internal Revenue.

**BSP** – Bangko Sentral ng Pilipinas.

**Consulting Services** – Refer to services for Infrastructure Projects and other types of projects or activities of the GOP requiring adequate external technical and professional expertise that are beyond the capability and/or capacity of the GOP to undertake such as, but not limited to: (i) advisory and review services; (ii) pre-investment or feasibility studies; (iii) design; (iv) construction supervision; (v) management and related services; and (vi) other technical services or special studies. (2016 revised IRR, Section 5[i])

**CDA** - Cooperative Development Authority.

**Contract** – Refers to the agreement entered into between the Procuring Entity and the Supplier or Manufacturer or Distributor or Service Provider for procurement of Goods and Services; Contractor for Procurement of Infrastructure Projects; or Consultant or Consulting Firm for Procurement of Consulting Services; as the case may be, as recorded in the Contract Form signed by the parties, including all attachments and appendices thereto and all documents incorporated by reference therein.

**CIF** – Cost Insurance and Freight.

**CIP** – Carriage and Insurance Paid.

**CPI** – Consumer Price Index.

**DDP** – Refers to the quoted price of the Goods, which means “delivered duty paid.”

**DTI** – Department of Trade and Industry.

**EXW** – Ex works.

**FCA** – “Free Carrier” shipping point.

**FOB** – “Free on Board” shipping point.

**Foreign-funded Procurement or Foreign-Assisted Project**–Refers to procurement whose funding source is from a foreign government, foreign or international financing institution as specified in the Treaty or International or Executive Agreement. (2016 revised IRR, Section 5[b]).

**Framework Agreement** – Refers to a written agreement between a procuring entity and a supplier or service provider that identifies the terms and conditions, under which specific purchases, otherwise known as “Call-Offs,” are made for the duration of the agreement. It is in the nature of an option contract between the procuring entity and the bidder(s) granting the procuring entity the option to either place an order for any of the goods or services identified in the Framework Agreement List or not buy at all, within a minimum period of one (1) year to a maximum period of three (3) years. (GPPB Resolution No. 27-2019)

**GFI** – Government Financial Institution.

**GOCC** –Government-owned and/or –controlled corporation.

**Goods** – Refer to all items, supplies, materials and general support services, except Consulting Services and Infrastructure Projects, which may be needed in the transaction of public businesses or in the pursuit of any government undertaking, project or activity, whether in the nature of equipment, furniture, stationery, materials for construction, or personal property of any kind, including non-personal or contractual services such as the repair and maintenance of equipment and furniture, as well as trucking, hauling, janitorial, security, and related or analogous services, as well as procurement of materials and supplies provided by the Procuring Entity for such services. The term “related” or “analogous services” shall include, but is not limited to, lease or purchase of office space, media advertisements, health maintenance services, and other services essential to the operation of the Procuring Entity. (2016 revised IRR, Section 5[r])

**GOP** – Government of the Philippines.

**GPPB** – Government Procurement Policy Board.

**INCOTERMS** – International Commercial Terms.

**Infrastructure Projects** – Include the construction, improvement, rehabilitation, demolition, repair, restoration or maintenance of roads and bridges, railways, airports, seaports, communication facilities, civil works components of information technology projects, irrigation, flood control and drainage, water supply, sanitation, sewerage and solid waste management systems, shore protection, energy/power and electrification facilities, national

buildings, school buildings, hospital buildings, and other related construction projects of the government. Also referred to as *civil works or works*. (2016 revised IRR, Section 5[u])

**LGUs** – Local Government Units.

**NFCC** – Net Financial Contracting Capacity.

**NGA** – National Government Agency.

**PhilGEPS** - Philippine Government Electronic Procurement System.

**Procurement Project** – refers to a specific or identified procurement covering goods, infrastructure project or consulting services. A Procurement Project shall be described, detailed, and scheduled in the Project Procurement Management Plan prepared by the agency which shall be consolidated in the procuring entity's Annual Procurement Plan. (GPPB Circular No. 06-2019 dated 17 July 2019)

**PSA** – Philippine Statistics Authority.

**SEC** – Securities and Exchange Commission.

**SLCC** – Single Largest Completed Contract.

**Supplier** – refers to a citizen, or any corporate body or commercial company duly organized and registered under the laws where it is established, habitually established in business and engaged in the manufacture or sale of the merchandise or performance of the general services covered by his bid. (Item 3.8 of GPPB Resolution No. 13-2019, dated 23 May 2019). Supplier as used in these Bidding Documents may likewise refer to a distributor, manufacturer, contractor, or consultant.

**UN** – United Nations.

## ***Section I. Invitation to Bid***

### **Notes on the Invitation to Bid**

The Invitation to Bid (IB) provides information that enables potential Bidders to decide whether to participate in the procurement at hand. The IB shall be posted in accordance with Section 21.2 of the 2016 revised IRR of RA No. 9184.

Apart from the essential items listed in the Bidding Documents, the IB should also indicate the following:

- a. The date of availability of the Bidding Documents, which shall be from the time the IB is first advertised/posted until the deadline for the submission and receipt of bids;
- b. The place where the Bidding Documents may be acquired or the website where it may be downloaded;
- c. The deadline for the submission and receipt of bids; and
- d. Any important bid evaluation criteria (*e.g.*, the application of a margin of preference in bid evaluation).

The IB should be incorporated in the Bidding Documents. The information contained in the IB must conform to the Bidding Documents and in particular to the relevant information in the Bid Data Sheet.





University of the Philippines  
The Health Sciences Center  
**BIDS & AWARDS COMMITTEE 1**  
BAC Office, PGH Compound  
Taft Avenue, Manila  
Tel. No. 554-8400 local 3014 / 3015



## INVITATION TO BID FOR *Supply and Delivery of Various Drugs and Medicines – Ampules and Vials Resale for CY2023 (Framework Agreement)*

1. The *University of the Philippines Manila – Philippine General Hospital (UPM-PGH)*, using a *single-year* for a duration of *one (1) year* Framework Agreement, through the *General Appropriations Act CY 2023* intends to apply the sum of **Three Hundred Ten Million Seven Hundred Seventy Seven Thousand Four Hundred Twelve Pesos & 77/100 (PhP310,777,412.77)** inclusive of all taxes, such as, but not limited to, value added tax (VAT), income tax, local taxes, and other fiscal levies, *being the ABC to payments under the contract for each item. Bids received in excess of the total cost per item shall be automatically rejected.*
2. The *University of the Philippines Manila – Philippine General Hospital (UPM-PGH)* now invites bids for *Supply and Delivery of Various Drugs and Medicines – Ampules and Vials Resale for CY2023 (Framework Agreement)*. Delivery of the Goods will be on staggered basis. Bidders should have completed, within two (2) years from the date of submission and receipt of bids, a contract similar to the Project. The description of an eligible bidder is contained in the Bidding Documents, particularly, in Section II (Instructions to Bidders).
3. Bidding will be conducted through open competitive bidding procedures using a non-discretionary “*pass/fail*” criterion as specified in the 2016 revised Implementing Rules and Regulations (IRR) of Republic Act (RA) No. 9184

Bidding is restricted to Filipino citizens/sole proprietorships, partnerships, or organizations with at least sixty percent (60%) interest or outstanding capital stock belonging to citizens of the Philippines, and to citizens or organizations of a country the laws or regulations of which grant similar rights or privileges to Filipino citizens, pursuant to RA No. 5183.

4. Prospective Bidders may obtain further information from UPM-PGH BAC Secretariat and inspect the Bidding Documents at the address given below during office hours from 8:00AM to 4:30PM.
5. A complete set of Bidding Documents may be acquired by interested Bidders on **18 November 2022** from the given address and website(s) below upon payment of the applicable fee for the Bidding Documents, pursuant to the latest Guidelines issued by the GPPB, in the amount of (to be determined upon issuance of bid documents). The Procuring Entity shall allow the bidder to present its proof of payment for the fees in person, or through electronic means.

6. The UPM-PGH will hold a **Pre-Bid Conference** on **02 December 2022, 9:30 AM** at **Bids and Awards Committee 1(BAC1) Office, PGH Compound Taft Avenue Manila** and/or through video conferencing or webcasting *via ZOOM*, which shall be open to prospective bidders.
7. Bids must be duly received by the BAC Secretariat through manual submission at the office address indicated below, on or before **9:00AM, 16 December 2022**. Late bids shall not be accepted.
8. All Bids must be accompanied by a bid security in any of the acceptable forms and in the amount stated in **ITB** Clause 14.
9. Bid opening shall be on 9:30AM, 16 December 2022 at the given address below. Bids will be opened in the presence of the bidders' representatives who choose to attend the activity.
10. The UPM-PGH reserves the right to reject any and all bids, declare a failure of bidding, or not award the contract at any time prior to contract award in accordance with Sections 35.6 and 41 of the 2016 revised IRR of RA No. 9184, without thereby incurring any liability to the affected bidder or bidders.
11. For further information, please refer to:  
  
BAC 1 Secretariat  
UP-Philippine General Hospital  
PGH Compound, Taft Avenue, Manila  
Telephone No.: 8-554-8400 local 3014/3015  
e-Mail Address: [bac1pgh.upm@up.edu.ph](mailto:bac1pgh.upm@up.edu.ph)
12. You may visit the following websites:  
  
For downloading of Bidding Documents: [www.philgeps.gov.ph](http://www.philgeps.gov.ph) and <https://bidsandawards.up.edu.ph>

---

**Dean CHARLOTTE M. CHIONG, MD, PhD**  
*Chairperson*

## ***Section II. Instructions to Bidders***

### **Notes on the Instructions to Bidders**

This Section on the Instruction to Bidders (ITB) provides the information necessary for bidders to prepare responsive bids, in accordance with the requirements of the ***University of the Philippines Manila – Philippine General Hospital***. It also provides information on bid submission, eligibility check, opening and evaluation of bids, post-qualification, and on the award of contract.

## 1. Scope of Bid

The Procuring Entity, UPM-PGH wishes to receive Bids for the ***Supply and Delivery of Various Drugs and Medicines – Ampules/Vials Resale for CY 2023*** under a Framework Agreement, with identification number ***BAC1-2022-11-0077-A***

The Procurement Project (referred to herein as “Project”) is composed of *one hundred seventy eight (178) items*, the details of which are described in Section VII (Technical Specifications).

## 2. Funding Information

2.1. The GOP through the source of funding as indicated below for ***General Appropriations Act CY 2023*** in the amount of **Three Hundred Ten Million Seven Hundred Seventy-Seven Thousand Four Hundred Twelve Pesos & 77/100 (Php310,777,412.77)**

2.2. The source of funding is:

a. NGA, the National Expenditure Program.

## 3. Bidding Requirements

The Bidding for the Project shall be governed by all the provisions of RA No. 9184 and its 2016 revised IRR, including its Generic Procurement Manuals and associated policies, rules and regulations as the primary source thereof, while the herein clauses shall serve as the secondary source thereof.

Any amendments made to the IRR and other GPPB issuances shall be applicable only to the ongoing posting, advertisement, or **ITB** by the BAC through the issuance of a supplemental or bid bulletin.

The Bidder, by the act of submitting its Bid, shall be deemed to have verified and accepted the general requirements of this Project, including other factors that may affect the cost, duration and execution or implementation of the contract, project, or work and examine all instructions, forms, terms, and project requirements in the Bidding Documents.

## 4. Corrupt, Fraudulent, Collusive, and Coercive Practices

The Procuring Entity, as well as the Bidders and Suppliers, shall observe the highest standard of ethics during the procurement and execution of the contract. They or through an agent shall not engage in corrupt, fraudulent, collusive, coercive, and obstructive practices defined under Annex “I” of the 2016 revised IRR of RA No. 9184 or other integrity violations in competing for the Project.

## 5. Eligible Bidders

5.1. Only Bids of Bidders found to be legally, technically, and financially capable will be evaluated.

- 5.2. Foreign ownership exceeding those allowed under the rules may participate pursuant to:
- i. When a Treaty or International or Executive Agreement as provided in Section 4 of the RA No. 9184 and its 2016 revised IRR allow foreign bidders to participate;
  - ii. Citizens, corporations, or associations of a country, included in the list issued by the GPPB, the laws or regulations of which grant reciprocal rights or privileges to citizens, corporations, or associations of the Philippines;
  - iii. When the Goods sought to be procured are not available from local suppliers; or
  - iv. When there is a need to prevent situations that defeat competition or restrain trade.
- 5.3. Pursuant to Section 23.4.1.3 of the 2016 revised IRR of RA No.9184, the Bidder shall have an SLCC that is at least one (1) contract similar to the Project the value of which, adjusted to current prices using the PSA's CPI, must be at least equivalent to:
- a. For the procurement of Non-expendable Supplies and Services: The Bidder must have completed a single contract that is similar to this Project, equivalent to at least fifty percent (50%) of the ABC.
  - b. For the procurement of Expendable Supplies: The Bidder must have completed a single contract that is similar to this Project, equivalent to at least twenty-five percent (25%) of the ABC.
  - c. For procurement where the Procuring Entity has determined, after the conduct of market research, that imposition of either (a) or (b) will likely result to failure of bidding or monopoly that will defeat the purpose of public bidding: the Bidder should comply with the following requirements: *[Select either failure or monopoly of bidding based on market research conducted]*
    - i. Completed at least two (2) similar contracts, the aggregate amount of which should be equivalent to at least *fifty percent (50%) in the case of non-expendable supplies and services or twenty-five percent (25%) in the case of expendable supplies* of the ABC for this Project; and
    - ii. The largest of these similar contracts must be equivalent to at least half of the percentage of the ABC as required above.
- 5.4. The Bidders shall comply with the eligibility criteria under Section 23.4.1 of the 2016 IRR of RA No. 9184.

## 6. Origin of Goods

There is no restriction on the origin of goods other than those prohibited by a decision of the UN Security Council taken under Chapter VII of the Charter of the UN, subject to Domestic Preference requirements under **ITB** Clause 18.

## 7. Subcontracts

7.1. The Bidder may subcontract portions of the Project to the extent allowed by the Procuring Entity as stated herein, but in no case more than twenty percent (20%) of the Project.

The Procuring Entity has prescribed that:

- a. Subcontracting is not allowed.

## 8. Pre-Bid Conference

The Procuring Entity will hold a pre-bid conference for this Project on the specified date and time and either at its physical address at the **BAC Conference Room, BAC Office PGH Compound Taft Avenue Ermita Manila** and/or through **ZOOM** as indicated in paragraph 6 of the **IB**.

## 9. Clarification and Amendment of Bidding Documents

Prospective bidders may request for clarification on and/or interpretation of any part of the Bidding Documents. Such requests must be in writing and received by the Procuring Entity, either at its given address or through electronic mail indicated in the **IB**, at least ten (10) calendar days before the deadline set for the submission and receipt of Bids.

## 10. Documents comprising the Bid: Eligibility and Technical Components

- 10.1. The first envelope shall contain the eligibility and technical documents of the Bid as specified in **Section VIII (Checklist of Technical and Financial Documents)**.
- 10.2. The Bidder's SLCC as indicated in **ITB** Clause 5.3 should have been completed within prior to the deadline for the submission and receipt of bids.
- 10.3. If the eligibility requirements or statements, the bids, and all other documents for submission to the BAC are in foreign language other than English, it must be accompanied by a translation in English, which shall be authenticated by the appropriate Philippine foreign service establishment, post, or the equivalent office having jurisdiction over the foreign bidder's affairs in the Philippines. Similar to the required authentication above, for Contracting Parties to the Apostille Convention, only the translated documents shall be authenticated through an apostille pursuant to GPPB Resolution No. 13-2019 dated 23 May 2019. The English translation shall govern, for purposes of interpretation of the bid.

## 11. Documents comprising the Bid: Financial Component

- 11.1. The second bid envelope shall contain the financial documents for the Bid as specified in **Section VIII (Checklist of Technical and Financial Documents)**.
- 11.2. If the Bidder claims preference as a Domestic Bidder or Domestic Entity, a certification issued by DTI shall be provided by the Bidder in accordance with Section 43.1.3 of the 2016 revised IRR of RA No. 9184.
- 11.3. Any bid exceeding the ABC indicated in paragraph 1 of the **IB** shall not be accepted.
- 11.4. For Foreign-funded Procurement, a ceiling may be applied to bid prices provided the conditions are met under Section 31.2 of the 2016 revised IRR of RA No. 9184.
- 11.5. Financial proposals for single or multi-year Framework Agreement shall be submitted before the deadline of submission of bids as prescribed in the **IB**. For multi-year Framework Agreement, evaluation of the financial proposal during this stage is for purposes of determining eligibility and whether or not such financial proposal is within the ABC.

## 12. Bid Prices

- 12.1. Prices indicated on the Price Schedule shall be entered separately in the following manner:
  - a. For Goods offered from within the Procuring Entity's country:
    - i. The price of the Goods quoted EXW (ex-works, ex-factory, ex-warehouse, ex-showroom, or off-the-shelf, as applicable);
    - ii. The cost of all customs duties and sales and other taxes already paid or payable;
    - iii. The cost of transportation, insurance, and other costs incidental to delivery of the Goods to their final destination; and
    - iv. The price of other (incidental) services, if any, listed in e.
  - b. For Goods offered from abroad:
    - i. Unless otherwise stated in the **BDS**, the price of the Goods shall be quoted delivered duty paid (DDP) with the place of destination in the Philippines as specified in the **BDS**. In quoting the price, the Bidder shall be free to use transportation through carriers registered in any eligible country. Similarly, the Bidder may obtain insurance services from any eligible source country.

- ii. The price of other (incidental) services, if any, as listed in **Section VII (Technical Specifications)**.

12.2. For Framework Agreement, the following should also apply in addition to Clause 12.1:

- a. For a single year Framework Agreement, the prices quoted by the Bidder shall be fixed during the Bidder's performance of the contract and not subject to variation or escalation on any account. Price schedules required under Clause 12.1 shall be submitted with the bidding documents.
- b. For a multi-year Framework Agreement, the prices quoted by the Bidder during submission of eligibility documents shall be the ceiling and the price quoted during mini-competition must not exceed the initial price offer. The price quoted during call for mini-competition shall be fixed during the Bidder's performance of that Call-off and not subject to variation or escalation on any account. Price schedules required under Clause 12.1 shall be submitted with the bidding documents.

### 13. Bid and Payment Currencies

- 13.1. For Goods that the Bidder will supply from outside the Philippines, the bid prices may be quoted in the local currency or tradeable currency accepted by the BSP at the discretion of the Bidder. However, for purposes of bid evaluation, Bids denominated in foreign currencies, shall be converted to Philippine currency based on the exchange rate as published in the BSP reference rate bulletin on the day of the bid opening.
- 13.2. Payment of the contract price shall be made in:
  - a. Philippine Pesos.

### 14. Bid Security

- 14.1. The Bidder shall submit a Bid Securing Declaration<sup>1</sup> or any form of Bid Security in the amount indicated+ in the **BDS**, which shall be not less than the percentage of the ABC in accordance with the schedule in the **BDS**.
- 14.2. The Bid and bid security shall be valid until *one hundred twenty (120) calendar days from the date of opening of bids*. Any Bid not accompanied by an acceptable bid security shall be rejected by the Procuring Entity as non-responsive.
- 14.3. In the case of Framework Agreement, other than the grounds for forfeiture under the 2016 revised IRR, the bid security may also be forfeited if the successful bidder fails to sign the Framework Agreement, or fails to furnish the performance security or performance securing declaration. Without prejudice on its forfeiture, bid securities shall be returned only after the posting of performance security or performance securing declaration, as the case may be, by the winning Bidder or compliant Bidders and the signing of the Framework Agreement.

---

<sup>1</sup> In the case of Framework Agreement, the undertaking shall refer to entering into contract with the Procuring Entity and furnishing of the performance security or the performance securing declaration within ten (10) calendar days from receipt of Notice to Execute Framework Agreement.



## **15. Sealing and Marking of Bids**

Each Bidder shall submit one copy of the first and second components of its Bid.

The Procuring Entity may request additional hard copies and/or electronic copies of the Bid. However, failure of the Bidders to comply with the said request shall not be a ground for disqualification.

If the Procuring Entity allows the submission of bids through online submission or any other electronic means, the Bidder shall submit an electronic copy of its Bid, which must be digitally signed. An electronic copy that cannot be opened or is corrupted shall be considered non-responsive and, thus, automatically disqualified.

## **16. Deadline for Submission of Bids**

16.1. The Bidders shall submit on the specified date and time and either at its physical address or through online submission as indicated in paragraph 7 of the **IB**.

16.2. For multi-year Framework Agreement, the submission of bids shall be for the initial evaluation of their technical and financial eligibility. Thereafter, those declared eligible during the said initial eligibility evaluation and entered into a Framework Agreement with the Procuring Entity shall submit anew their best financial offer at the address and on or before the date and time indicated in the Call for each mini-competition.

## **17. Opening and Preliminary Examination of Bids**

17.1. The BAC shall open the Bids in public at the time, on the date, and at the place specified in paragraph 9 of the **IB**. The Bidders' representatives who are present shall sign a register evidencing their attendance. In case videoconferencing, webcasting or other similar technologies will be used, attendance of participants shall likewise be recorded by the BAC Secretariat.

In case the Bids cannot be opened as scheduled due to justifiable reasons, the rescheduling requirements under Section 29 of the 2016 revised IRR of RA No. 9184 shall prevail.

17.2. The preliminary examination of bids shall be governed by Section 30 of the 2016 revised IRR of RA No. 9184.

## **18. Domestic Preference**

18.1. The Procuring Entity will grant a margin of preference for the purpose of comparison of Bids in accordance with Section 43.1.2 of the 2016 revised IRR of RA No. 9184.

18.2. For multi-year Framework Agreement, determination of margin of preference shall be conducted every call for Mini-Competition.

## 19. Detailed Evaluation and Comparison of Bids

- 19.1. The Procuring BAC shall immediately conduct a detailed evaluation of all Bids rated “*passed*,” using non-discretionary pass/fail criteria. The BAC shall consider the conditions in the evaluation of Bids under Section 32.2 of the 2016 revised IRR of RA No. 9184.
- a. In the case of single-year Framework Agreement, the Lowest Calculated Bid shall be determined outright after the detailed evaluation;
  - b. For multi-year Framework Agreement, the determination of the eligibility and the compliance of bidders with the technical and financial aspects of the projects shall be initially made by the BAC, in accordance with Item 7.4.2 of the Guidelines on the Use of Framework Agreement.
- 19.2. If the Project allows partial bids, bidders may submit a proposal on any of the lots or items, and evaluation will be undertaken on a per lot or item basis, as the case may be. In this case, the Bid Security as required by **ITB** Clause 15 shall be submitted for each lot or item separately.
- 19.3. The descriptions of the lots or items shall be indicated in **Section VII (Technical Specifications)**, although the ABCs of these lots or items are indicated in the **BDS** for purposes of the NFCC computation pursuant to Section 23.4.2.6 of the 2016 revised IRR of RA No. 9184. The NFCC must be sufficient for the total of the ABCs for all the lots or items participated in by the prospective Bidder.
- 19.4. The Project shall be awarded as follows:
- Option 1 – One Project having several items that shall be awarded as one contract.
- 19.5. Except for bidders submitting a committed Line of Credit from a Universal or Commercial Bank in lieu of its NFCC computation, all Bids must include the NFCC computation pursuant to Section 23.4.1.4 of the 2016 revised IRR of RA No. 9184, which must be sufficient for the total of the ABCs for all the lots or items participated in by the prospective Bidder. For bidders submitting the committed Line of Credit, it must be at least equal to ten percent (10%) of the ABCs for all the lots or items participated in by the prospective Bidder.

## 20. Post-Qualification

- 20.1. For multi-year Framework Agreement, all bidders initially determined to be eligible and financially compliant shall be subject to initial post-qualification. The BAC shall then recommend the execution of a Framework Agreement among all eligible, technically and financially compliant bidders and the Procuring Entity and shall be issued by HoPE a Notice to Execute Framework Agreement. The determination of the Lowest Calculated Bid (LCB) shall not be performed by the BAC until a Mini-Competition is conducted among the bidders who executed a Framework Agreement. When a Call for Mini-Competition is made, the BAC shall allow the bidders to submit their best

financial proposals on such pre-scheduled date, time and place to determine the bidder with the LCB.

- 20.2. Within a non-extendible period of five (5) calendar days from receipt by the Bidder of the notice from the BAC that it submitted the Lowest Calculated Bid, or in the case of multi-year Framework Agreement, that it is one of the eligible bidders who have submitted bids that are found to be technically and financially compliant, }the Bidder shall submit its latest income and business tax returns filed and paid through the BIR Electronic Filing and Payment System (eFPS) and other appropriate licenses and permits required by law and stated in the **BDS**. For every mini-competition in Framework Agreement, the LCB shall likewise submit the required documents for final Post Qualification. }

## 21. Signing of the Contract

- 21.1. The documents required in Section 37.2 of the 2016 revised IRR of RA No. 9184 shall form part of the Contract. Additional Contract documents are indicated in the **BDS**.
- 21.2. At the same time as the Procuring Entity notifies the successful Bidder that its bid has been accepted, the Procuring Entity shall send the Framework Agreement Form to the Bidder, which contract has been provided in the Bidding Documents, incorporating therein all agreements between the parties.
- 21.3. Within ten (10) calendar days from receipt of the Notice to Execute Framework Agreement with the Procuring Entity, the successful Bidder or its duly authorized representative shall formally enter into a Framework Agreement with the procuring entity for an amount of One Peso to be paid to the procuring entity as a consideration for the option granted by the procuring entity to procure the items in the Framework Agreement List when the need arises.
- 21.4. The Procuring Entity shall enter into a Framework Agreement with the successful Bidder within the same ten (10) calendar day period provided that all the documentary requirements are complied with.
- 21.5. The following documents shall form part of the Framework Agreement:
- a. Framework Agreement Form;
  - b. Bidding Documents;
  - c. Call-offs;
  - d. Winning bidder's bid, including the Technical and Financial Proposals, and all other documents/statements submitted (*e.g.*, bidder's response to request for clarifications on the bid), including corrections to the bid, if any, resulting from the Procuring Entity's bid evaluation;
  - e. Performance Security or Performance Securing Declaration, as the case may be;
  - f. Notice to Execute Framework Agreement; and
  - g. Other contract documents that may be required by existing laws and/or specified in the **BDS**.

## ***Section III. Bid Data Sheet***

### **Notes on the Bid Data Sheet**

The Bid Data Sheet (BDS) consists of provisions that supplement, amend, or specify in detail, information, or requirements included in the ITB found in Section II, which are specific to each procurement.

This Section is intended to assist the ***University of the Philippines Manila – Philippine General Hospital*** in providing the specific information in relation to corresponding clauses in the ITB and has to be prepared for each specific procurement.

The ***University of the Philippines Manila – Philippine General Hospital*** should specify in the BDS information and requirements specific to the circumstances of the ***University of the Philippines Manila – Philippine General Hospital***, the processing of the procurement, and the bid evaluation criteria that will apply to the Bids. In preparing the BDS, the following aspects should be checked:

- a. Information that specifies and complements provisions of the ITB must be incorporated.
- b. Amendments and/or supplements, if any, to provisions of the ITB as necessitated by the circumstances of the specific procurement, must also be incorporated.

# Bid Data Sheet

ITB Clause					
5.3	For this purpose, contracts similar to the Project shall be: <ul style="list-style-type: none"> <li>a. <b><i>Drugs and Medicines</i></b></li> <li>b. completed within two (2) years prior to the deadline for the submission and receipt of bids.</li> </ul>				
7.1	<i>Subcontracting is not allowed</i>				
12	The price of the Goods shall be quoted DDP <i>University of the Philippines Manila – Philippine General Hospital</i> for the applicable International Commercial Terms (INCOTERMS) for this Project.				
14.1	The bid security shall be in the form of a Bid Securing Declaration, or any of the following forms and amounts:				
	a. The amount of not less than <i>the amount equivalent to two percent (2%) of ABC</i> , if bid security is in cash, cashier's/manager's check, bank draft/guarantee or irrevocable letter of credit; or				
	b. The amount of not less than <i>the amount equivalent to five percent (5%) of ABC</i> if bid security is in Surety Bond.				
19.3	ITEM NO.	QTY	UOM	ITEM DESCRIPTION (AGENCY'S REQUIREMENTS)	ABC PER UNIT (PHP)
	1	80	pc	Acetylcysteine 200mg/mL, 25mL vial/bottle (IV infusion)	1,813.00
	2	2,400	pc	Aciclovir 25mg/mL, 10mL vial (IV infusion)	977.43
	3	1,900	pc	Albumin Human 20%, 50mL bottle (IV, IV infusion)	2,100.00
	4	32	pc	Adenosine 3 mg/mL, 2 mL vial (IV)	1,960.00
	5	1,240	pc	Amikacin sulfate 125mg/mL , 2mL ampule/vial (IM, IV)	386.00
	6	1,200	pc	Amikacin sulfate 250mg/mL , 2mL ampule/vial (IM, IV)	97.44
	7	2	pc	Aminophylline (theophylline ethylenediamine) 25 mg/mL, 10 mL ampul (IV)	45.00
	8	971	pc	Amiodarone hydrochloride 50 mg/mL, 3 mL ampul (IV)	448.00
	9	30	pc	Amphotericin B non lipid complex 50mg lyophilized powder, vial (IV infusion)	2,448.00

10	30	pc	Amphotericin B Lipid Complex (as cholesteryl complex, colloidal dispersion) 50 mg vial (IV infusion)	13,499.00
11	5,000	pc	Ampicillin + Sulbactam 1000 mg ampicillin + 500 mg sulbactam (IM, IV) (as sodium salt) per vial	310.00
12	3,120	pc	Ampicillin + Sulbactam 500 mg ampicillin + 250 mg sulbactam (IM, IV) (as sodium salt) per vial	210.00
13	2,340	pc	Ampicillin sodium 250mg vial (IM, IV)	37.85
14	2,250	pc	Ampicillin sodium 500mg vial (IM, IV)	54.00
15	20	pc	Asparaginase lyophilized powder, 10,000 IU vial (IV)	1,700.00
16	110	pc	Atracurium besilate 10mg/mL, 2.5mL ampule (IV)	230.00
17	585	pc	Atropine sulfate 1mg/mL, 1 mL ampul (IM, IV, SC)	18.69
18	480	pc	Azithromycin 500 mg powder, vial (IV infusion) (as base*/as dihydrate)	540.00
19	1,000	pc	Aztreonam 1g powder for injection (IV, IV Infusion)	1,142.35
20	4	pc	Beractant 25 mg/ml suspension, 8mL Intratracheal administration vial	17,354.18
21	2	pc	Beractant 25 mg/mL suspension, 4 mL Intratracheal administration vial	11,070.25
22	2	pc	Bleomycin sulfate powder, 15 IU ampul/vial (IM,IV)	2,750.00
23	100	pc	Bupivacaine Hydrochloride 0.5% 4 mL ampul (spinal) with 8% dextrose	457.00
24	70	pc	Bupivacaine Hydrochloride 0.5%, 10mL ampul/vial (local infiltration)	341.78
25	5	pc	Butorphanol tartrate 2 mg/mL, 1 mL ampul/vial (IM, IV)	508.93
26	1,200	pc	Calcium folinate (leucovorin Ca) 10mg/mL, 5mL ampule/vial (IM, IV)	180.00
27	4,820	pc	Calcium Gluconate 10%, 10 mL ampul/vial (IV)	164.00
28	30	pc	Carbetocin 100 mcg/mL, 1 mL ampule/vial, solution for Injection (IV)	1,200.00
29	150	pc	Carboprost 125 mcg/0.5 mL solution for injection, 0.5 mL ampul/vial	289.00
30	40	pc	Carboprost 250 mcg/mL solution for injection, 1 mL ampule/vial	500.00
31	6,010	pc	Cefazolin sodium 1gm vial (IM, IV)	215.00
32	200	pc	Cefepime Hydrochloride 1gm vial (IM, IV)	312.50
33	1,440	pc	Cefepime Hydrochloride 2gms vial (IM, IV)	441.10

34	120	pc	Cefotaxime sodium 500 mg vial + 2 mL diluent (IM, IV)	740.50
35	36,640	pc	Cefoxitin sodium 1gm vial (IM, IV)	800.00
36	8,000	pc	Ceftazidime pentahydrate 1gm vial (IM, IV)	210.00
37	12,454	pc	Ceftriaxone disodium/sodium 1gm vial + 10mL diluent (IV)	368.00
38	50	pc	Cefuroxime sodium 250mg vial (IM, IV)	232.75
39	8,510	pc	Cefuroxime sodium 750mg vial (IM, IV)	90.00
40	1,030	pc	Ciprofloxacin lactate 2mg/mL, 100mL vial (IV infusion)	241.08
41	1,560	pc	Clindamycin phosphate 150mg/mL, 2mL ampule/vial (IM, IV)	198.00
42	2,840	pc	Clindamycin phosphate 150mg/mL, 4mL ampule (IM, IV)	370.00
43	15	pc	Clonidine hydrochloride 150mcg/mL, 1mL ampule (IV)	183.15
44	200	pc	Colistin 2,000,000 IU lyophilized powder for injection (IV infusion)	2,232.14
45	10	pc	Cytarabine 100 mg/mL solution for injection, 1 mL	130.00
46	2	pc	Cytarabine 100 mg/mL solution for injection, 5 mL	376.00
47	2	pc	Cytarabine 100 mg/mL solution for injection, 10 mL	1,607.14
48	10	pc	Dactinomycin powder, 500 micrograms vial (IV)	440.00
49	203	pc	Deferoxamine mesilate powder, 500 mg vial (IM, IV infusion, SC)	183.32
50	4,650	pc	Dexamethasone sodium phosphate 4 mg/mL, 2 mL ampul/vial (IM, IV)	69.00
51	10,000	pc	Dexamethasone sodium phosphate 5mg/mL, 1mL ampule (IM, IV)	67.23
52	220	pc	Diazepam 5 mg/mL, 2 mL ampul (IM, IV) (With PDEA Permit)	138.22
53	55	pc	Digoxin 250 micrograms/mL, 2 mL ampul (IM, IV)	310.00
54	4,575	pc	Diphenhydramine Hydrochloride 50 mg/mL, 1 mL ampul (IM, IV)	98.00
55	531	pc	Dobutamine Hydrochloride 50mg/mL, 5ml ampule (IV infusion)	490.00
56	570	pc	Dopamine Hydrochloride 40mg/mL 5mL vial/ampule (IV)	234.50
57	20	pc	Doxorubicin Hydrochloride powder, 10mg vial or 2mg/mL, 5mL vial (IV)	165.00
58	20	pc	Doxorubicin Hydrochloride powder, 50mg vial or 2mg/mL, 25mL vial (IV)	500.20
59	8	pc	Enoxaparin sodium 100mg/mL, 0.2mL pre-filled syringe (SC)	479.00

60	10,070	pc	Enoxaparin sodium 100mg/mL, 0.4mL pre-filled syringe (SC)	794.00
61	2,545	pc	Enoxaparin sodium 100mg/mL, 0.6mL pre-filled syringe (SC)	778.00
62	3,295	pc	Epinephrine Hydrochloride 1mg/mL, 1mL ampule (IV, IM, SC)	80.00
63	300	pc	Epoetin alfa (recombinant human erythropoietin) 10,000 IU/mL, pre-filled syringe (IV, SC)	1,458.00
64	7,200	pc	Epoetin alfa (recombinant human erythropoietin) 4000 IU/0.4 mL, pre-filled syringe (IV, SC)	950.00
65	4	pc	Epoetin alfa (recombinant human erythropoietin) 2000 IU/0.5 mL, pre-filled syringe (IV, SC)	542.86
66	2	pc	Epoetin Beta (recombinant erythropoietin) 2000 IU/0.3 mL, pre-filled syringe with needle (IV, SC)	530.00
67	2,450	pc	Epoetin Beta (recombinant erythropoietin) 5000 IU/0.3 mL, pre-filled syringe with needle (IV, SC)	1,272.18
68	500	pc	Ertapenem sodium 1gm powder vial (IM/IV)	2,818.98
69	24	pc	Esmolol Hydrochloride 10mg/mL, 10mL vial (IV)	686.34
70	120	pc	Famotidine 20 mg powder/lyophilized powder for injection, ampule/vial (IV)	134.03
71	20,170	pc	Fentanyl citrate 50mcg/mL, 2mL amp (IV) (With PDEA Permit)	374.44
72	19,800	pc	Filgrastim 300 micrograms/1.2 mL, vial (IV, SC) or 300 micrograms/mL, vial (IV, SC)	1,590.00
73	960	pc	Fluconazole 2mg/mL, 100mL vial (IV infusion)	600.00
74	15	pc	Fluphenazine (as decanoate) 25mg/mL, 1mL ampule (IM)	79.44
75	12	pc	Fluorouracil 50 mg/mL, 10 mL ampul/vial (IV, IV infusion)	74.80
76	10	pc	Fondaparinux sodium 2.5 mg/0.5 mL solution (IV, SC)	3,500.00
77	20,230	pc	Furosemide 10 mg/mL, 2 mL ampul (IM, IV)	20.00
78	14	pc	Ganciclovir sodium 500 mg vial (IV infusion)	2,299.90
79	2	pc	Gemcitabine Hydrochloride 1gm vial (IV infusion)	2,987.00
80	2	pc	Gemcitabine Hydrochloride 200mg vial (IV infusion)	722.00
81	730	pc	Gentamicin sulfate 40mg/mL, 2mL ampule/vial (IM, IV)	14.88
82	6,000	pc	Glucose (dextrose) 50%, 50mL vial (IV)	114.00



83	50	pc	Glyceryl trinitrate (nitroglycerin) 1mg/mL, 10mL ampule (IV infusion)	436.80
84	20	pc	Haloperidol 5 mg/mL, 1 mL ampul (IM)	730.00
85	740	pc	Heparin sodium unfractionated 1,000 iu/mL, 5mL vial (IV infusion, SC) (bovine origin)	135.00
86	580	pc	Heparin sodium unfractionated 5000 IU/mL, 5 mL vial (IV infusion, SC) (bovine origin)	262.34
87	4	pc	Human recombinant tissue type plasminogen activator (alteplase) 50 mg powder for I.V. infusion	30,536.02
88	26	pc	Hydralazine Hydrochloride 20 mg/mL, 1 mL ampul (IM, IV)	232.00
89	7,350	pc	Hydrocortisone sodium succinate 50mg/mL, 2mL vial or 100mg powder vial (IV)	164.45
90	328	pc	Hydrocortisone sodium succinate 125 mg/mL, 2 mL vial (IV) or 250 mg powder vial (IV)	370.00
91	960	pc	Hyoscine-n-butylbromide 20mg/mL, 1mL ampule (IM, IV, SC)	35.00
92	2	pc	Ifosfamide powder, 2gms vial (IV infusion)	2,900.00
93	2	pc	Ifosfamide powder, 1g vial (IV infusion)	1,500.00
94	770	pc	Insulin, regular( recombinant DNA human) 100 IU/mL, 10mL vial (SC, IV/IM)	810.00
95	1,440	pc	Insulin, Biphasic Isophane Human 70/30 (recombinant DNA) 70% isophane suspension + 30% soluble insulin in 100 IU/mL, 10 mL vial (SC)	595.00
96	540	pc	Isophane Insulin Human (recombinant DNA) 100 IU/mL, 10 mL vial (SC)	425.00
97	320	pc	Isosorbide dinitrate 1mg/ml, 10mL ampule (IV)	540.00
98	820	pc	Iron sucrose 20mg/mL, 5mL ampule (IV, IV infusion)	200.00
99	20	pc	Isoxsuprine hydrochloride 5 mg/mL, 2 mL ampul (IM, IV infusion)	260.00
100	10	pc	Ketamine hydrochloride 50 mg/mL, 10 mL vial (IM, IV) (With PDEA Permit)	1,499.00
101	10,900	pc	Ketorolac tromethamol 30 mg/mL, 1 mL ampul (IM, IV)	25.00
102	70	pc	Leuproreline (as acetate) powder, 3.75mg single dose with syringe (IM, SC)	4,642.00
103	1,500	pc	Levetiracetam 500 mg/5 mL (100 mg/mL) concentrate solution for IV infusion, 5 mL vial	1,908.00

104	1,540	pc	Levofloxacin 5 mg/mL solution for IV infusion, 100mL vial	965.00
105	720	pc	Lidocaine Hydrochloride 2% (20 mg/mL), 2 mL ampul/vial (IM/IV)	39.50
106	4,030	pc	Lidocaine Hydrochloride 2%, 5mL ampule/vial (IM/IV)	46.00
107	6	pc	Lidocaine Hydrochloride 2%, 50mL ampule/vial (IM, IV)	51.00
108	2	pc	Lidocaine Hydrochloride 2%, 1.8 mL carpule (with epinephrine) (local infiltration)	27.00
109	300	pc	Linezolid 2 mg/mL (600 mg/300 mL), solution for infusion (IV)	4,152.50
110	3,060	pc	Magnesium sulfate heptahydrate 250mg/mL, 20mL vial (IV)	95.00
111	38,684	pc	Meropenem trihydrate 1g powder vial (IV)	850.00
112	33,600	pc	Meropenem trihydrate 500mg powder vial (IV)	550.00
113	1,400	pc	Mesna (sodium-2mercapto ethanesulphonate) 100mg/mL, 4mL ampule (IV)	161.70
114	100	pc	Methotrexate 25 mg/mL, 2 mL ampul/vial (IM, IV, Intrathecal) (as base)	205.50
115	92	pc	Methylergonovine (methylergonovine) (as hydrogen maleate or maleate) 200 micrograms/mL, 1 mL ampul (IM, IV)	64.00
116	20	pc	Methylprednisolone 40 mg in single dose vial, solution for injection (IV, IM) (as sodium succinate)	716.85
117	240	pc	Methylprednisolone lyophilized powder, 500 mg vial (IM, IV) (as sodium succinate)	2,403.50
118	9,870	pc	Metoclopramide 5mg/mL, 2mL ampule (As Base and As Hydrochloride) (IM/IV)	20.00
119	3,800	pc	Metronidazole 5 mg/mL, 100 mL vial (IV infusion)	57.00
120	4,700	pc	Midazolam 1mg/mL, 5mL ampule or 5mg/mL, 1mL ampule (IM, IV) (With PDEA Permit)	155.00
121	11,575	pc	Midazolam 5mg/mL, 3mL ampule (IM, IV) (With PDEA Permit)	589.98
122	500	pc	Milrinone 10mg/ml, 10ml ampule (IV) (With Compassionate Special Permit)	890.40
123	920	pc	Morphine Sulfate 10 mg/mL, 1 mL ampul (IM, IV, SC) or 16 mg/mL, 1 mL ampul (IM, IV) (With PDEA Permit)	70.00

124	416	pc	Nalbuphine Hydrochloride 10 mg/mL, 1 mL ampul (IM, IV, SC) (With PDEA Permit)	102.78
125	5	pc	Naloxone hydrochloride 400 micrograms/mL, 1 mL ampul (IM, IV, SC)	272.48
126	60	pc	Neostigmine 500 mcg/mL solution for injection (IM/IV/SC), 1 mL ampule	126.50
127	60	pc	Nicardipine Hydrochloride 1mg/mL, 2mL ampule (IV)	389.90
128	31,142	pc	Nicardipine Hydrochloride 1mg/mL, 10mL ampule (IV)	660.00
129	5,000	pc	Norepinephrine bitartrate 1mg/mL, 2mL ampule (IV infusion)	210.00
130	9,630	pc	Norepinephrine bitartrate 1mg/mL, 4mL ampule (IV infusion)	400.00
131	800	pc	Octreotide acetate 100 micrograms/mL ampul (IV infusion)	650.00
132	17,460	pc	Omeprazole powder, 40 mg vial + 10 mL solvent ampul/vial (IV)	335.00
133	4,525	pc	Ondansetron 2mg/mL, 2mL ampule (IM, IV)	730.00
134	5,000	pc	Ondansetron 2mg/mL, 4mL ampule (IM, IV)	450.00
135	9,610	pc	Oxacillin sodium 500mg vial (IM, IV)	130.00
136	544	pc	Oxytocin (synthetic) 10 IU/mL, 1 mL ampul (IM, IV)	241.90
137	75,550	pc	Paracetamol 150mg/mL, 2mL ampule solution for injection (IM, IV)	26.00
138	1,000	pc	Paracetamol 10 mg/mL, 50 mL vial solution for infusion (IV)	217.80
139	1,200	pc	Paracetamol 10 mg/mL, 100 mL vial solution for infusion (IV)	200.00
140	85	pc	Penicillin G benzathine (benzathine benzylpenicillin) 1,200,000 units vial (MR) (IM)	190.00
141	30	pc	Penicillin G crystalline (benzylpenicillin) sodium 1,000,000 units vial (IM, IV)	18.00
142	10	pc	Penicillin G crystalline (benzylpenicillin) sodium 5,000,000 units vial (IM, IV)	21.00
143	10	pc	Pethidine (meperidine) (as hydrochloride) 50 mg/mL, 2 mL ampul (IM, IV, SC) (With PDEA Permit)	253.78
144	2	pc	Phenylephrine hydrochloride 10mg/1mL vial (With Compassionate Special Permit) (IV/IV Infusion)	554.40
145	20	pc	Phenytoin sodium 50mg/mL, 2mL ampule (IV)	650.00

146	5,100	pc	Phytomenadione (phytonadione, vitamin K1) 10mg/mL, 1mL ampul (IM, IV, SC) (as mixed micelle)	45.89
147	37,464	pc	Piperacillin + Tazobactam (as sodium salt) 2 g piperacillin + 250 mg tazobactam per vial (IV infusion)	310.00
148	73,087	pc	Piperacillin + Tazobactam (as sodium salt) 4 g piperacillin + 500 mg tazobactam per vial (IV infusion)	295.00
149	1,500	pc	Polymyxin B sulfate 500,000 Units powder for solution for injection (Intrathecal/IM/IV), 5 mL vial	2,793.96
150	3,890	pc	Potassium chloride 2meq/mL, 20mL vial (IV infusion)	57.00
151	150	pc	Propofol 10mg/mL, 20mL ampule/vial (IV)	563.73
152	2	pc	Protamine sulfate 10mg/mL, 5mL ampule (IV) (With Compassionate Special Permit)	678.00
153	870	pc	Ranitidine hydrochloride 25 mg/mL, 2 mL ampul/vial (IM, IV, IV infusion)	23.78
154	10	pc	Rocuronium bromide 10 mg/mL, 5 mL ampul/vial (IV)	218.18
155	7,200	pc	Sodium Bicarbonate 1 mEq/mL, 20 mL ampul/vial (adult) (IV infusion)	179.88
156	4,012	pc	Sodium bicarbonate 1mEq/mL, 50mL ampul/vial (adult) (IV infusion)	205.00
157	2,415	pc	Sodium Chloride 2.5mEq/mL, 20mL vial	55.00
158	600	pc	Sodium Chloride 0.9% 2mL ampul	10.00
159	60	pc	Sodium Chloride 0.9% 20mL ampul	25.85
160	45	pc	Somatostatin 250mcg ampule/vial (IV, IV infusion)	719.80
161	300	pc	Somatostatin 3mg ampule/vial (IV, IV infusion)	4,630.90
162	27	pc	Streptokinase powder, 1,500,000 IU vial (IV infusion)	3,980.00
163	17	pc	Streptomycin sulfate 1 g vial (IM)	28.00
164	12	pc	Sugammadex 100 mg/mL solution for injection (IV), 2 mL vial	5,782.70
165	18	pc	Suxamethonium (succinylcholine) chloride 20 mg/mL, 10 mL vial (IV)	300.00
166	45	pc	Terbutaline sulfate 500mcg/mL, 1mL ampule (IM, IV, SC)	48.28
167	10	pc	Tinzaparin (as sodium) 10,000 anti-Xa IU/mL, 0.45 mL pre-filled syringe (SC)	238.31
168	10,090	pc	Tramadol Hydrochloride 50mg/mL, 1mL ampule (IM, IV, SC)	41.00

169	5,100	pc	Tramadol Hydrochloride 50mg/mL, 2mL ampule (IM, IV, SC)	95.00
170	9,940	pc	Tranexamic acid 100mg/mL, 5mL ampule (IM, IV)	130.00
171	34,170	pc	Vancomycin Hydrochloride 500mg vial (IV)	995.00
172	960	pc	Vasopressin 20 IU/mL (IM, IV)	1,490.00
173	20	pc	Verapamil Hydrochloride 2.5 mg/mL, 2 mL ampul (IV)	127.94
174	2	pc	Vinblastine sulfate 1 mg/mL, 10 mL vial (IV)	1,001.00
175	250	pc	Vincristine sulfate 1 mg/mL, 1 mL vial (IV)	395.88
176	250	pc	Vincristine sulfate 1 mg/mL, 2 mL vial (IV)	436.15
177	32	pc	Vitamin B1 B6 B12 100 mg B1 + 100 mg B6 + 1 mg B12 per 3 mL ampul (IV)	35.00
178	20	pc	Voriconazole 200mg lyophilized powder for solution for IV infusion, 30mLVial	5,167.80
<b>TOTAL APPROVED BUDGET FOR THE CONTRACT: PhP310,777,412.77</b>				
<b><i>Terms and Conditions:</i></b>				
1. Indicate the <b>brand and packing of the item/s</b> offered.				
2. The brand offered must be <b><u>at least five (5) years</u> commercially available in the market from date of opening of bids</b> . Proof of this shall be the initial Certificate of Product Registration (CPR) issued by the Food and Drug Administration (FDA).				
3. <b>Submit the following documents, submission should be per product, with tab and per item number. <u>Two (2) copies for the Valid Certificate of Product Registration and Certificate of Analysis (COA).</u></b>				
3.1 <b>Memorandum of Agreement (MOA) and Certificate of exclusive/authorized distributorship between the manufacturer and distributor.</b> Distributors/suppliers must have certification from their principals that they are the exclusive distributor of the drug products authorized to submit tender for the product on behalf of the principal and that all commitments made by them shall be honored by the principal in case of termination of distributorship agreement.				
3.2 <b>Valid Certificate of Product Registration (CPR)</b> issued by the Food and Drug Administration (FDA). <ul style="list-style-type: none"> <li><b>The name of the respective distributor should appear in the submitted CPR of the drug.</b></li> </ul> <p><i>Note: CPRs that will expire within three (3) months from the date of opening of bids should present the Official Receipt of renewal of application with the Document Tracking log for the CPR from the FDA.</i></p>				
3.3 <b>Certificate of Analysis (COA)</b> for the products offered (batch to be delivered if awarded) duly issued by an FDA accredited laboratory (local) and should contain information indicated in monograph of the drug. Sample analyzed must not be expired during the time of bidding. The result of assay submitted must be in the specific brand and should be in the exact dosage formulation of the drug being bid. In cases where local laboratories are unavailable to perform drug assays,				

	assays done abroad is accepted. The local COA is preferred and given more weight in the evaluation and awarding process.
	3.4 <b>A notarized certificate</b> that it is the innovator drug (if applicable).
	3.5 <b>Certificate of Current Good Manufacturing Practice (CGMP).</b>
	3.6 <b>Valid License to Operate (LTO).</b>
	<b>3.7 A notarized certificate that the offered brand has not been subject to product complaint/product recall for the past three (3) years.</b>
	<b>3.8 Certificate of Acceptance</b> from at least three (3) major hospital issued within the year and should be supported with Sales Invoice ( <i>for new item/brand offered only</i> ).
	<b>3.9 A notarized certificate</b> that there are sufficient stocks for the offered item/s for one (1) year.
	4. The offered drug must conform to the latest Philippine Food and Drug Administration (FDA) Administrative Order <b>governing the generic labeling and packaging requirements.</b>
	<b>4.1 For all tablets and capsules</b>
	<b>4.1.1 All tablets/capsules should be in foil or blister pack. A picture of the blister pack (front and back) should be submitted.</b>
	4.1.2 Each individual flap in the tablet or capsule blister pack should be labeled with the generic name and brand.
	4.1.3 Dosage form and strength of the Active Pharmaceutical Ingredients (API) should appear on each unit or every 2 units for products with multiple APIs.
	4.1.4 Name of drug, lot or batch number and expiry date must appear on every standard blister pack/foil strip and on the container or inner packing. However, if the product is not restricted for dispensing in quantities less than the standard blister pack or foil strip, the batch or lot number and expiry date should appear on each unit.
	4.1.5 Inner label must be the same as the outer label.
	4.1.6 A complete drug literature/product insert must accompany the product.
	5. The following must be complied with specific for <b>cytotoxic injectable drugs.</b>
	5.1 For cytotoxic injectable drugs, winning bidders are required to <i>provide Material Safety Data Sheet (MSDS) and to submit Drug Profile</i> to the Pharmacy Department per company under the first Purchase Order.
	5.2 Winning bidders for cytotoxic injectable drugs are required to <b>provide at least three (3) spill kits</b> per company under the first Purchase Order.
	6. The brand offered on all antibiotics must have stability that is equivalent to that of the innovator product or better.
	7. <b>New brands offered</b> shall be subject to further evaluation and shall require the following:
	7.1. Validation of the submitted Certificate of Acceptance from at least three (3) major hospitals
	7.2. Justification from end-user/s to validate the acceptance of the good/s offered (to be facilitated by PGH-PSD).
	<b>8. For the supply and delivery of awarded drugs and medicines.</b>

	8.1.Delivery of the goods is required as stated in the request of the end-user, commencing on the 3rd working day of notification through confirmed fax/email that the approved Call-off/ Notice to Supplier (NTS) is already available for pick up.
	8.2.Delivery schedule (whichever is applicable): 8.2.1. within seven (7) calendar days; 8.2.2. as may be called for; 8.2.3. staggered delivery within three (3) months * 50% of the total quantity within seven (7) calendar days and 25% each for the succeeding months <i>Note: The end-user has the right to adjust the quantity to be delivered depending on the actual need of the hospital</i>
	8.3.Deliveries shall have <b>at least two (2) years expiration date.</b>
	8.4.Delivery of goods <b>with product complaint shall be put on hold</b> until receipt of the final decision of the PGH management whether to proceed with the acceptance or to cancel/return the items
	8.5.Delivered <b>items found to be non-formulary at any given time shall be returned</b> to the company and a credit memo shall be issued.
	8.6.Stocks delivered are subject to random sampling for testing as to quality and conformity to label. Testing fee at supplier's expense.
	8.7.Stocks with lot #/batch different from the submitted Certificate of Analysis (COA) will be subjected to testing as to quality and conformity to label. <u>Testing fee at supplier's expense.</u>
	8.8.All items that had been pulled out for various reasons, a credit memo shall be issued by the Contractor within one (1) month, otherwise, a debit memo shall be processed by UP Manila - PGH and the amount will be deducted from any amount due to Supplier.
	8.9.It is understood that the Supplier is legally responsible to deliver all issued <b>CALL-OFF/s</b> (Purchase Order) and <b>failure to deliver the first Call-Off as scheduled shall mean automatic cancellation of the Call-Off and Notice to Execute Framework Agreement (NEFA).</b> Purchase from other source for whatever means shall be effected immediately to provide the requirements of the hospital. Penalty to the defaulting contractor shall be charged accordingly.
	<b>9. Failure to comply with the submission of the required documents shall be ground for post-disqualification in accordance with RA 9184.</b>
	10. Compliance with RA 9184 and other applicable laws.
20.2	1. Latest Income and Business Tax returns filed and paid through the BIR Electronic Filing and Payment System (eFPS) 2. License to Operate (LTO) if applicable.
21.2	Not applicable

## ***Section IV. General Conditions of Contract***

### **Notes on the General Conditions of Contract**

The General Conditions of Contract (GCC) in this Section, read in conjunction with the Special Conditions of Contract in Section V and other documents listed therein, should be a complete document expressing all the rights and obligations of the parties.

Matters governing performance of the Supplier, payments under the contract, or matters affecting the risks, rights, and obligations of the parties under the contract are included in the GCC and Special Conditions of Contract.

Any complementary information, which may be needed, shall be introduced only through the Special Conditions of Contract.



## **1. Scope of Contract**

This Contract shall include all such items, although not specifically mentioned, that can be reasonably inferred as being required for its completion as if such items were expressly mentioned herein. All the provisions of RA No. 9184 and its 2016 revised IRR, including the Generic Procurement Manual, and associated issuances, constitute the primary source for the terms and conditions of the Contract, and thus, applicable in contract implementation. Herein clauses shall serve as the secondary source for the terms and conditions of the Contract.

This is without prejudice to Sections 74.1 and 74.2 of the 2016 revised IRR of RA No. 9184 allowing the GPPB to amend the IRR, which shall be applied to all procurement activities, the advertisement, posting, or invitation of which were issued after the effectivity of the said amendment.

Additional requirements for the completion of this Contract shall be provided in the **Special Conditions of Contract (SCC)**.

## **2. Advance Payment and Terms of Payment**

- 2.1. Advance payment of the contract amount is provided under Annex “D” of the revised 2016 IRR of RA No. 9184.
- 2.2. The Procuring Entity is allowed to determine the terms of payment on the partial or staggered delivery of the Goods procured, provided such partial payment shall correspond to the value of the goods delivered and accepted in accordance with prevailing accounting and auditing rules and regulations. The terms of payment are indicated in the **SCC**.
- 2.3. For a single-year Framework Agreement, prices charged by the Supplier for Goods delivered and/or services performed under a Call-Off shall not vary from the prices quoted by the Supplier in its bid.
- 2.4. For multi-year Framework Agreement, prices charged by the Supplier for Goods delivered and/or services performed under a Call-Off shall not vary from the prices quoted by the Supplier during conduct of Mini-Competition.

## **3. Performance Security**

Within ten (10) calendar days from receipt of the Notice of Award by the Bidder from the Procuring Entity but in no case later than prior to the signing of the Contract by both parties, the successful Bidder shall furnish the performance security in any of the forms prescribed in Section 39 of the 2016 revised IRR of RA No. 9184. *In the case of Framework Agreement, the Bidder may opt to furnish the performance security or a Performance Securing Declaration as defined under the Guidelines on the Use of Framework Agreement.*

#### **4. Inspection and Tests**

The Procuring Entity or its representative shall have the right to inspect and/or to test the Goods to confirm their conformity to the Project or Framework Agreement specifications at no extra cost to the Procuring Entity in accordance with the Generic Procurement Manual. In addition to tests in the **SCC, Section IV (Technical Specifications)** shall specify what inspections and/or tests the Procuring Entity requires, and where they are to be conducted. The Procuring Entity shall notify the Supplier in writing, in a timely manner, of the identity of any representatives retained for these purposes.

All reasonable facilities and assistance for the inspection and testing of Goods, including access to drawings and production data, shall be provided by the Supplier to the authorized inspectors at no charge to the Procuring Entity.

#### **5. Warranty**

- 6.1. In order to assure that manufacturing defects shall be corrected by the Supplier, a warranty shall be required from the Supplier as provided under Section 62.1 of the 2016 revised IRR of RA No. 9184.
- 6.2. The Procuring Entity shall promptly notify the Supplier in writing of any claims arising under this warranty. Upon receipt of such notice, the Supplier shall, repair or replace the defective Goods or parts thereof without cost to the Procuring Entity, pursuant to the Generic Procurement Manual.

#### **6. Liability of the Supplier**

The Supplier's liability under this Contract shall be as provided by the laws of the Republic of the Philippines.

If the Supplier is a joint venture, all partners to the joint venture shall be jointly and severally liable to the Procuring Entity.

## ***Section V. Special Conditions of Contract***

### **Notes on the Special Conditions of Contract**

Similar to the BDS, the clauses in this Section are intended to assist the Procuring Entity in providing contract-specific information in relation to corresponding clauses in the GCC found in Section IV.

The Special Conditions of Contract (SCC) complement the GCC, specifying contractual requirements linked to the special circumstances of the Procuring Entity, the Procuring Entity's country, the sector, and the Goods purchased. In preparing this Section, the following aspects should be checked:

- a. Information that complements provisions of the GCC must be incorporated.
- b. Amendments and/or supplements to provisions of the GCC as necessitated by the circumstances of the specific purchase, must also be incorporated.

However, no special condition which defeats or negates the general intent and purpose of the provisions of the GCC should be incorporated herein.

## Special Conditions of Contract

GCC Clause	
1	<p><b>Delivery and Documents –</b></p> <p>For purposes of the Contract, “EXW,” “FOB,” “FCA,” “CIF,” “CIP,” “DDP” and other trade terms used to describe the obligations of the parties shall have the meanings assigned to them by the current edition of INCOTERMS published by the International Chamber of Commerce, Paris. The Delivery terms of this Contract shall be as follows:</p> <p><i>[For Goods supplied from abroad, state:]</i> “The delivery terms applicable to the Contract are DDP delivered <i>[indicate place of destination]</i>. In accordance with INCOTERMS.”</p> <p>“The delivery terms applicable to this Contract are delivered <i>[indicate place of destination]</i>. Risk and title will pass from the Supplier to the <b><i>University of the Philippines Manila – Philippine General Hospital</i></b> upon receipt and final acceptance of the Goods at their final destination.”</p> <p>Delivery of the Goods shall be made by the Supplier in accordance with the terms specified in Section VI (Schedule of Requirements).</p> <p>For purposes of this Clause the Procuring Entity’s Representative at the Project Site is the assigned staff.</p> <p><b>Incidental Services –</b></p> <p>The Supplier is required to provide all of the following services, including additional services, if any, specified in Section VI. Schedule of Requirements:</p> <ol style="list-style-type: none"> <li>a. performance or supervision of on-site assembly and/or start-up of the supplied Goods;</li> <li>b. furnishing of tools required for assembly and/or maintenance of the supplied Goods;</li> <li>c. furnishing of a detailed operations and maintenance manual for each appropriate unit of the supplied Goods;</li> <li>d. training of the Procuring Entity’s personnel, at the Supplier’s plant and/or on-site, in assembly, start-up, operation, maintenance, and/or repair of the supplied Goods.</li> </ol> <p>The Contract price for the Goods shall include the prices charged by the Supplier for incidental services and shall not exceed the prevailing rates charged to other parties by the Supplier for similar services.</p>
	<p><b>Spare Parts –</b></p> <p>The Supplier is required to provide all of the following materials, notifications, and information pertaining to spare parts manufactured or distributed by the Supplier:</p>

	<p>a. such spare parts as the <i>University of the Philippines Manila – Philippine General Hospital</i> may elect to purchase from the Supplier, provided that this election shall not relieve the Supplier of any warranty obligations under this Contract; and</p> <p>b. in the event of termination of production of the spare parts:</p> <ol style="list-style-type: none"> <li>i. advance notification to the Procuring Entity of the pending termination, in sufficient time to permit the Procuring Entity to procure needed requirements; and</li> <li>ii. following such termination, furnishing at no cost to the Procuring Entity, the blueprints, drawings, and specifications of the spare parts, if requested.</li> </ol> <p>The spare parts and other components required are listed in <b>Section VI (Schedule of Requirements)</b> and the cost thereof are included in the contract price.</p> <p>The Supplier shall carry sufficient inventories to assure ex-stock supply of consumable spare parts or components for the Goods for a period of [<i>See attached Terms and Conditions</i>].</p> <p>Spare parts or components shall be supplied as promptly as possible, but in any case, within [<i>See attached Terms and Conditions</i>] months of placing the order.</p>
	<p><b>Packaging –</b></p> <p>The Supplier shall provide such packaging of the Goods as is required to prevent their damage or deterioration during transit to their final destination, as indicated in this Contract. The packaging shall be sufficient to withstand, without limitation, rough handling during transit and exposure to extreme temperatures, salt and precipitation during transit, and open storage. Packaging case size and weights shall take into consideration, where appropriate, the remoteness of the Goods’ final destination and the absence of heavy handling facilities at all points in transit.</p> <p>The packaging, marking, and documentation within and outside the packages shall comply strictly with such special requirements as shall be expressly provided for in the Contract, including additional requirements, if any, specified below, and in any subsequent instructions ordered by the Procuring Entity.</p>
	<p>The outer packaging must be clearly marked on at least four (4) sides as follows:</p> <p>Name of the Procuring Entity  Name of the Supplier  Contract Description  Final Destination  Gross weight  Any special lifting instructions  Any special handling instructions  Any relevant HAZCHEM classifications</p>

	<p>A packaging list identifying the contents and quantities of the package is to be placed on an accessible point of the outer packaging if practical. If not practical the packaging list is to be placed inside the outer packaging but outside the secondary packaging.</p> <p><b>Transportation –</b></p> <p>Where the Supplier is required under Contract to deliver the Goods CIF, CIP, or DDP, transport of the Goods to the port of destination or such other named place of destination in the Philippines, as shall be specified in this Contract, shall be arranged and paid for by the Supplier, and the cost thereof shall be included in the Contract Price.</p> <p>Where the Supplier is required under this Contract to transport the Goods to a specified place of destination within the Philippines, defined as the Project Site, transport to such place of destination in the Philippines, including insurance and storage, as shall be specified in this Contract, shall be arranged by the Supplier, and related costs shall be included in the contract price.</p>
	<p>Where the Supplier is required under Contract to deliver the Goods CIF, CIP or DDP, Goods are to be transported on carriers of Philippine registry. In the event that no carrier of Philippine registry is available, Goods may be shipped by a carrier which is not of Philippine registry provided that the Supplier obtains and presents to the <i>University of the Philippines Manila – Philippine General Hospital</i> certification to this effect from the nearest Philippine consulate to the port of dispatch. In the event that carriers of Philippine registry are available but their schedule delays the Supplier in its performance of this Contract the period from when the Goods were first ready for shipment and the actual date of shipment the period of delay will be considered force majeure.</p>
	<p>The <i>University of the Philippines Manila – Philippine General Hospital</i> accepts no liability for the damage of Goods during transit other than those prescribed by INCOTERMS for DDP deliveries. In the case of Goods supplied from within the Philippines or supplied by domestic Suppliers risk and title will not be deemed to have passed to the <i>University of the Philippines Manila – Philippine General Hospital</i> until their receipt and final acceptance at the final destination.</p>
	<p><b>Intellectual Property Rights –</b></p> <p>The Supplier shall indemnify the <i>University of the Philippines Manila – Philippine General Hospital</i> against all third-party claims of infringement of patent, trademark, or industrial design rights arising from use of the Goods or any part thereof.</p>
4	<p>The inspections and tests that will be conducted are: <i>[Indicate the applicable inspections and tests]</i></p>

## Section VI. Framework Agreement List

Limited to repeatedly required goods and services that are identified to be necessary and desirable, but, by its nature, use or characteristic, the quantity and/ or exact time of need cannot be accurately pre-determined and are not advisable to be carried in stock.

Prepared by the End-User, attached to the APP and submitted to the BAC for the approval of the HOPE.

<b>FRAMEWORK AGREEMENT LIST (AGENCY)</b>				
<b><i>Item / Service Type and nature of each item/service</i></b>		<b><i>Unit Cost per item or service</i></b>	<b><i>Maximum Quantity</i></b>	<b><i>Total Cost per Item</i></b>
1	Acetylcysteine 200mg/mL, 25mL vial/bottle (IV infusion)	1,813.00	80	145,040.00
2	Aciclovir 25mg/mL, 10mL vial (IV infusion)	977.43	2,400	2,345,832.00
3	Albumin Human 20%, 50mL bottle (IV, IV infusion)	2,100.00	1,900	3,990,000.00
4	Adenosine 3 mg/mL, 2 mL vial (IV)	1,960.00	32	62,720.00
5	Amikacin sulfate 125mg/mL , 2mL ampule/vial (IM, IV)	386.00	1,240	478,640.00
6	Amikacin sulfate 250mg/mL , 2mL ampule/vial (IM, IV)	97.44	1,200	116,928.00
7	Aminophylline (theophylline ethylenediamine) 25 mg/mL, 10 mL ampul (IV)	45.00	2	90.00
8	Amiodarone hydrochloride 50 mg/mL, 3 mL ampul (IV)	448.00	971	435,008.00
9	Amphotericin B non lipid complex 50mg lyophilized powder, vial (IV infusion)	2,448.00	30	73,440.00
10	Amphotericin B Lipid Complex (as cholesteryl complex, colloidal dispersion) 50 mg vial (IV infusion)	13,499.00	30	404,970.00
11	Ampicillin + Sulbactam 1000 mg ampicillin + 500 mg sulbactam (IM, IV) (as sodium salt) per vial	310.00	5,000	1,550,000.00
12	Ampicillin + Sulbactam 500 mg ampicillin + 250 mg sulbactam (IM, IV) (as sodium salt) per vial	210.00	3,120	655,200.00
13	Ampicillin sodium 250mg vial (IM, IV)	37.85	2,340	88,569.00
14	Ampicillin sodium 500mg vial (IM, IV)	54.00	2,250	121,500.00
15	Asparaginase lyophilized powder, 10,000 IU vial (IV)	1,700.00	20	34,000.00
16	Atracurium besilate 10mg/mL, 2.5mL ampule (IV)	230.00	110	25,300.00
17	Atropine sulfate 1mg/mL, 1 mL ampul (IM, IV, SC)	18.69	585	10,933.65

18	Azithromycin 500 mg powder, vial (IV infusion) (as base*/as dihydrate)	540.00	480	259,200.00
19	Aztreonam 1g powder for injection (IV, IV Infusion)	1,142.35	1,000	1,142,350.00
20	Beractant 25 mg/ml suspension, 8mL Intratracheal administration vial	17,354.18	4	69,416.72
21	Beractant 25 mg/mL suspension, 4 mL Intratracheal administration vial	11,070.25	2	22,140.50
22	Bleomycin sulfate powder, 15 IU ampul/vial (IM,IV)	2,750.00	2	5,500.00
23	Bupivacaine Hydrochloride 0.5% 4 mL ampul (spinal) with 8% dextrose	457.00	100	45,700.00
24	Bupivacaine Hydrochloride 0.5%, 10mL ampul/vial (local infiltration)	341.78	70	23,924.60
25	Butorphanol tartrate 2 mg/mL, 1 mL ampul/vial (IM, IV)	508.93	5	2,544.65
26	Calcium folinate (leucovorin Ca) 10mg/mL, 5mL ampule/vial (IM, IV)	180.00	1,200	216,000.00
27	Calcium Gluconate 10%, 10 mL ampul/vial (IV)	164.00	4,820	790,480.00
28	Carbetocin 100 mcg/mL, 1 mL ampule/vial, solution for Injection (IV)	1,200.00	30	36,000.00
29	Carboprost 125 mcg/0.5 mL solution for injection, 0.5 mL ampul/vial	289.00	150	43,350.00
30	Carboprost 250 mcg/mL solution for injection, 1 mL ampule/vial	500.00	40	20,000.00
31	Cefazolin sodium 1gm vial (IM, IV)	215.00	6,010	1,292,150.00
32	Cefepime Hydrochloride 1gm vial (IM, IV)	312.50	200	62,500.00
33	Cefepime Hydrochloride 2gms vial (IM, IV)	441.10	1,440	635,184.00
34	Cefotaxime sodium 500 mg vial + 2 mL diluent (IM, IV)	740.50	120	88,860.00
35	Cefoxitin sodium 1gm vial (IM, IV)	800.00	36,640	29,312,000.00
36	Ceftazidime pentahydrate 1gm vial (IM, IV)	210.00	8,000	1,680,000.00
37	Ceftriaxone disodium/sodium 1gm vial + 10mL diluent (IV)	368.00	12,454	4,583,072.00
38	Cefuroxime sodium 250mg vial (IM, IV)	232.75	50	11,637.50
39	Cefuroxime sodium 750mg vial (IM, IV)	90.00	8,510	765,900.00
40	Ciprofloxacin lactate 2mg/mL, 100mL vial (IV infusion)	241.08	1,030	248,312.40
41	Clindamycin phosphate 150mg/mL, 2mL ampule/vial (IM, IV)	198.00	1,560	308,880.00
42	Clindamycin phosphate 150mg/mL, 4mL ampule (IM, IV)	370.00	2,840	1,050,800.00



43	Clonidine hydrochloride 150mcg/mL, 1mL ampule (IV)	183.15	15	2,747.25
44	Colistin 2,000,000 IU lyophilized powder for injection (IV infusion)	2,232.14	200	446,428.00
45	Cytarabine 100 mg/mL solution for injection, 1 mL	130.00	10	1,300.00
46	Cytarabine 100 mg/mL solution for injection, 5 mL	376.00	2	752.00
47	Cytarabine 100 mg/mL solution for injection, 10 mL	1,607.14	2	3,214.28
48	Dactinomycin powder, 500 micrograms vial (IV)	440.00	10	4,400.00
49	Deferoxamine mesilate powder, 500 mg vial (IM, IV infusion, SC)	183.32	203	37,213.96
50	Dexamethasone sodium phoshate 4 mg/mL, 2 mL ampul/vial (IM, IV)	69.00	4,650	320,850.00
51	Dexamethasone sodium phoshate 5mg/mL, 1mL ampule (IM, IV)	67.23	10,000	672,300.00
52	Diazepam 5 mg/mL, 2 mL ampul (IM, IV) (With PDEA Permit)	138.22	220	30,408.40
53	Digoxin 250 micrograms/mL, 2 mL ampul (IM, IV)	310.00	55	17,050.00
54	Diphenhydramine Hydrochloride 50 mg/mL, 1 mL ampul (IM, IV)	98.00	4,575	448,350.00
55	Dobutamine Hydrochloride 50mg/mL, 5ml ampule (IV infusion)	490.00	531	260,190.00
56	Dopamine Hydrochloride 40mg/mL 5mL vial/ampule (IV)	234.50	570	133,665.00
57	Doxorubicin Hydrochloride powder, 10mg vial or 2mg/mL, 5mL vial (IV)	165.00	20	3,300.00
58	Doxorubicin Hydrochloride powder, 50mg vial or 2mg/mL, 25mL vial (IV)	500.20	20	10,004.00
59	Enoxaparin sodium 100mg/mL, 0.2mL pre-filled syringe (SC)	479.00	8	3,832.00
60	Enoxaparin sodium 100mg/mL, 0.4mL pre-filled syringe (SC)	794.00	10,070	7,995,580.00
61	Enoxaparin sodium 100mg/mL, 0.6mL pre-filled syringe (SC)	778.00	2,545	1,980,010.00
62	Epinephrine Hydrochloride 1mg/mL, 1mL ampule (IV, IM, SC)	80.00	3,295	263,600.00
63	Epoetin alfa (recombinant human erythropoetin) 10,000 IU/mL, pre-filled syringe (IV, SC)	1,458.00	300	437,400.00
64	Epoetin alfa (recombinant human erythropoetin) 4000 IU/0.4 mL, pre-filled syringe (IV, SC)	950.00	7,200	6,840,000.00

65	Epoetin alfa (recombinant human erythropoietin) 2000 IU/0.5 mL, pre-filled syringe (IV, SC)	542.86	4	2,171.44
66	Epoetin Beta (recombinant erythropoietin) 2000 IU/0.3 mL, pre-filled syringe with needle (IV, SC)	530.00	2	1,060.00
67	Epoetin Beta (recombinant erythropoietin) 5000 IU/0.3 mL, pre-filled syringe with needle (IV, SC)	1,272.18	2,450	3,116,841.00
68	Ertapenem sodium 1gm powder vial (IM/IV)	2,818.98	500	1,409,490.00
69	Esmolol Hydrochloride 10mg/mL, 10mL vial (IV)	686.34	24	16,472.16
70	Famotidine 20 mg powder/lyophilized powder for injection, ampule/vial (IV)	134.03	120	16,083.60
71	Fentanyl citrate 50mcg/mL, 2mL amp (IV) (With PDEA Permit)	374.44	20,170	7,552,454.80
72	Filgrastim 300 micrograms/1.2 mL, vial (IV, SC) or 300 micrograms/mL, vial (IV, SC)	1,590.00	19,800	31,482,000.00
73	Fluconazole 2mg/mL, 100mL vial (IV infusion)	600.00	960	576,000.00
74	Fluphenazine (as decanoate) 25mg/mL, 1mL ampule (IM)	79.44	15	1,191.60
75	Fluorouracil 50 mg/mL, 10 mL ampul/vial (IV, IV infusion)	74.80	12	897.60
76	Fondaparinux sodium 2.5 mg/0.5 mL solution (IV, SC)	3,500.00	10	35,000.00
77	Furosemide 10 mg/mL, 2 mL ampul (IM, IV)	20.00	20,230	404,600.00
78	Ganciclovir sodium 500 mg vial (IV infusion)	2,299.90	14	32,198.60
79	Gemcitabine Hydrochloride 1gm vial (IV infusion)	2,987.00	2	5,974.00
80	Gemcitabine Hydrochloride 200mg vial (IV infusion)	722.00	2	1,444.00
81	Gentamicin sulfate 40mg/mL, 2mL ampule/vial (IM, IV)	14.88	730	10,862.40
82	Glucose (dextrose) 50%, 50mL vial (IV)	114.00	6,000	684,000.00
83	Glyceryl trinitrate (nitroglycerin) 1mg/mL, 10mL ampule (IV infusion)	436.80	50	21,840.00
84	Haloperidol 5 mg/mL, 1 mL ampul (IM)	730.00	20	14,600.00
85	Heparin sodium unfractionated 1,000 iu/mL, 5mL vial (IV infusion, SC) (bovine origin)	135.00	740	99,900.00
86	Heparin sodium unfractionated 5000 IU/mL, 5 mL vial (IV infusion, SC) (bovine origin)	262.34	580	152,157.20
87	Human recombinant tissue type plasminogen activator (alteplase) 50 mg powder for I.V. infusion	30,536.02	4	122,144.08
88	Hydralazine Hydrochloride 20 mg/mL, 1 mL ampul (IM, IV)	232.00	26	6,032.00

89	Hydrocortisone sodium succinate 50mg/mL, 2mL vial or 100mg powder vial (IV)	164.45	7,350	1,208,707.50
90	Hydrocortisone sodium succinate 125 mg/mL, 2 mL vial (IV) or 250 mg powder vial (IV)	370.00	328	121,360.00
91	Hyoscine-n-butylbromide 20mg/mL, 1mL ampule (IM, IV, SC)	35.00	960	33,600.00
92	Ifosfamide powder, 2gms vial (IV infusion)	2,900.00	2	5,800.00
93	Ifosfamide powder, 1g vial (IV infusion)	1,500.00	2	3,000.00
94	Insulin, regular( recombinant DNA human) 100 IU/mL, 10mL vial (SC, IV/IM)	810.00	770	623,700.00
95	Insulin, Biphasic Isophane Human 70/30 (recombinant DNA) 70% isophane suspension + 30% soluble insulin in 100 IU/mL, 10 mL vial (SC)	595.00	1,440	856,800.00
96	Isophane Insulin Human (recombinant DNA) 100 IU/mL, 10 mL vial (SC)	425.00	540	229,500.00
97	Isosorbide dinitrate 1mg/ml, 10mL ampule (IV)	540.00	320	172,800.00
98	Iron sucrose 20mg/mL, 5mL ampule (IV, IV infusion)	200.00	820	164,000.00
99	Isoxsuprine hydrochloride 5 mg/mL, 2 mL ampul (IM, IV infusion)	260.00	20	5,200.00
100	Ketamine hydrochloride 50 mg/mL, 10 mL vial (IM, IV) (With PDEA Permit)	1,499.00	10	14,990.00
101	Ketorolac tromethamol 30 mg/mL, 1 mL ampul (IM, IV)	25.00	10,900	272,500.00
102	Leuporeline (as acetate) powder, 3.75mg single dose with syringe (IM, SC)	4,642.00	70	324,940.00
103	Levetiracetam 500 mg/5 mL (100 mg/mL) concentrate solution for IV infusion, 5 mL vial	1,908.00	1,500	2,862,000.00
104	Levofloxacin 5 mg/mL solution for IV infusion, 100mL vial	965.00	1,540	1,486,100.00
105	Lidocaine Hydrochloride 2% (20 mg/mL), 2 mL ampul/vial (IM/IV)	39.50	720	28,440.00
106	Lidocaine Hydrochloride 2%, 5mL ampule/vial (IM/IV)	46.00	4,030	185,380.00
107	Lidocaine Hydrochloride 2%, 50mL ampule/vial (IM, IV)	51.00	6	306.00
108	Lidocaine Hydrochloride 2%, 1.8 mL carpule (with epinephrine) (local infiltration)	27.00	2	54.00
109	Linezolid 2 mg/mL (600 mg/300 mL), solution for infusion (IV)	4,152.50	300	1,245,750.00
110	Magnesium sulfate heptahydrate 250mg/mL, 20mL vial (IV)	95.00	3,060	290,700.00

111	Meropenem trihydrate 1g powder vial (IV)	850.00	38,684	32,880,975.00
112	Meropenem trihydrate 500mg powder vial (IV)	550.00	33,600	18,480,000.00
113	Mesna (sodium-2mercapto ethanesulphonate) 100mg/mL, 4mL ampule (IV)	161.70	1,400	226,380.00
114	Methotrexate 25 mg/mL, 2 mL ampul/vial (IM, IV, Intrathecal) (as base)	205.50	100	20,550.00
115	Methylergometrine (methylergonovine) (as hydrogen maleate or maleate) 200 micrograms/mL, 1 mL ampul (IM, IV)	64.00	92	5,888.00
116	Methylprednisolone 40 mg in single dose vial, solution for injection (IV, IM) (as sodium succinate)	716.85	20	14,337.00
117	Methylprednisolone lyophilized powder, 500 mg vial (IM, IV) (as sodium succinate)	2,403.50	240	576,840.00
118	Metoclopramide 5mg/mL, 2mL ampule (As Base and As Hydrochloride) (IM/IV)	20.00	9,870	197,400.00
119	Metronidazole 5 mg/mL, 100 mL vial (IV infusion)	57.00	3,800	216,600.00
120	Midazolam 1mg/mL, 5mL ampule or 5mg/mL, 1mL ampule (IM, IV) (With PDEA Permit)	155.00	4,700	728,500.00
121	Midazolam 5mg/mL, 3mL ampule (IM, IV) (With PDEA Permit)	589.98	11,575	6,829,018.50
122	Milrinone 10mg/ml, 10ml ampule (IV) (With Compassionate Special Permit)	890.40	500	445,200.00
123	Morphine Sulfate 10 mg/mL, 1 mL ampul (IM, IV, SC) or 16 mg/mL, 1 mL ampul (IM, IV) (With PDEA Permit)	70.00	920	64,400.00
124	Nalbuphine Hydrochloride 10 mg/mL, 1 mL ampul (IM, IV, SC) (With PDEA Permit)	102.78	416	42,756.48
125	Naloxone hydrochloride 400 micrograms/mL, 1 mL ampul (IM, IV, SC)	272.48	5	1,362.40
126	Neostigmine 500 mcg/mL solution for injection (IM/IV/SC), 1 mL ampule	126.50	60	7,590.00
127	Nicardipine Hydrochloride 1mg/mL, 2mL ampule (IV)	389.90	60	23,394.00
128	Nicardipine Hydrochloride 1mg/mL, 10mL ampule (IV)	660.00	31,142	20,553,720.00
129	Norepinephrine bitartrate 1mg/mL, 2mL ampule (IV infusion)	210.00	5,000	1,050,000.00
130	Norepinephrine bitartrate 1mg/mL, 4mL ampule (IV infusion)	400.00	9,630	3,852,000.00
131	Octreotide acetate 100 micrograms/mL ampul (IV infusion)	650.00	800	520,000.00

132	Omeprazole powder, 40 mg vial + 10 mL solvent ampul/vial (IV)	335.00	17,460	5,849,100.00
133	Ondansetron 2mg/mL, 2mL ampule (IM, IV)	730.00	4,525	3,303,250.00
134	Ondansetron 2mg/mL, 4mL ampule (IM, IV)	450.00	5,000	2,250,000.00
135	Oxacillin sodium 500mg vial (IM, IV)	130.00	9,610	1,249,300.00
136	Oxytocin (synthetic) 10 IU/mL, 1 mL ampul (IM, IV)	241.90	544	131,593.60
137	Paracetamol 150mg/mL, 2mL ampule solution for injection (IM, IV)	26.00	75,550	1,964,300.00
138	Paracetamol 10 mg/mL, 50 mL vial solution for infusion (IV)	217.80	1,000	217,800.00
139	Paracetamol 10 mg/mL, 100 mL vial solution for infusion (IV)	200.00	1,200	240,000.00
140	Penicillin G benzathine (benzathine benzylpenicillin) 1,200,000 units vial (MR) (IM)	190.00	85	16,150.00
141	Penicillin G crystalline (benzylpenicillin) sodium 1,000,000 units vial (IM, IV)	18.00	30	540.00
142	Penicillin G crystalline (benzylpenicillin) sodium 5,000,000 units vial (IM, IV)	21.00	10	210.00
143	Pethidine (meperidine) (as hydrochloride) 50 mg/mL, 2 mL ampul (IM, IV, SC) (With PDEA Permit)	253.78	10	2,537.80
144	Phenylephrine hydrochloride 10mg/1mL vial (With Compassionate Special Permit) (IV/IV Infusion)	554.40	2	1,108.80
145	Phenytoin sodium 50mg/mL, 2mL ampule (IV)	650.00	20	13,000.00
146	Phytomenadione (phytonadione, vitamin K1) 10mg/mL, 1mL ampul (IM, IV, SC) (as mixed micelle)	45.89	5,100	234,039.00
147	Piperacillin + Tazobactam (as sodium salt) 2 g piperacillin + 250 mg tazobactam per vial (IV infusion)	310.00	37,464	11,613,840.00
148	Piperacillin + Tazobactam (as sodium salt) 4 g piperacillin + 500 mg tazobactam per vial (IV infusion)	295.00	73,087	21,560,665.00
149	Polymyxin B sulfate 500,000 Units powder for solution for injection (Intrathecal/IM/IV), 5 mL vial	2,793.96	1,500	4,190,940.00
150	Potassium chloride 2meq/mL, 20mL vial (IV infusion)	57.00	3,890	221,730.00
151	Propofol 10mg/mL, 20mL ampule/vial (IV)	563.73	150	84,559.50
152	Protamine sulfate 10mg/mL, 5mL ampule (IV) (With Compassionate Special Permit)	678.00	2	1,356.00
153	Ranitidine hydrochloride 25 mg/mL, 2 mL ampul/vial (IM, IV, IV infusion)	23.78	870	20,688.60

154	Rocuronium bromide 10 mg/mL, 5 mL ampul/vial (IV)	218.18	10	2,181.80
155	Sodium Bicarbonate 1 mEq/mL, 20 mL ampul/vial (adult) (IV infusion)	179.88	7,200	1,295,136.00
156	Sodium bicarbonate 1mEq/mL, 50mL ampul/vial (adult) (IV infusion)	205.00	4,012	822,460.00
157	Sodium Chloride 2.5mEq/mL, 20mL vial	55.00	2,415	132,825.00
158	Sodium Chloride 0.9% 2mL ampul	10.00	600	6,000.00
159	Sodium Chloride 0.9% 20mL ampul	25.85	60	1,551.00
160	Somatostatin 250mcg ampule/vial (IV, IV infusion)	719.80	45	32,391.00
161	Somatostatin 3mg ampule/vial (IV, IV infusion)	4,630.90	300	1,389,270.00
162	Streptokinase powder, 1,500,000 IU vial (IV infusion)	3,980.00	27	107,460.00
163	Streptomycin sulfate 1 g vial (IM)	28.00	17	476.00
164	Sugammadex 100 mg/mL solution for injection (IV), 2 mL vial	5,782.70	12	69,392.40
165	Suxamethonium (succinylcholine) chloride 20 mg/mL, 10 mL vial (IV)	300.00	18	5,400.00
166	Terbutaline sulfate 500mcg/mL, 1mL ampule (IM, IV, SC)	48.28	45	2,172.60
167	Tinzaparin (as sodium) 10,000 anti-Xa IU/mL, 0.45 mL pre-filled syringe (SC)	238.31	10	2,383.10
168	Tramadol Hydrochloride 50mg/mL, 1mL ampule (IM, IV, SC)	41.00	10,090	413,690.00
169	Tramadol Hydrochloride 50mg/mL, 2mL ampule (IM, IV, SC)	95.00	5,100	484,500.00
170	Tranexamic acid 100mg/mL, 5mL ampule (IM, IV)	130.00	9,940	1,292,200.00
171	Vancomycin Hydrochloride 500mg vial (IV)	995.00	34,170	33,999,150.00
172	Vasopressin 20 IU/mL (IM, IV)	1,490.00	960	1,430,400.00
173	Verapamil Hydrochloride 2.5 mg/mL, 2 mL ampul (IV)	127.94	20	2,558.80

174	Vinblastine sulfate 1 mg/mL, 10 mL vial (IV)	1,001.00	2	2,002.00
175	Vincristine sulfate 1 mg/mL, 1 mL vial (IV)	395.88	250	98,970.00
176	Vincristine sulfate 1 mg/mL, 2 mL vial (IV)	436.15	250	109,037.50
177	Vitamin B1 B6 B12 100 mg B1 + 100 mg B6 + 1 mg B12 per 3 mL ampul (IV)	35.00	32	1,120.00
178	Voriconazole 200mg lyophilized powder for solution for IV infusion, 30mLVial	5,167.80	20	103,356.00
<b><i>TOTAL</i></b> <b><i>(Approved Budget for the Contract)</i></b>				<b>PhP310,777,412.77</b>
<i>Expected delivery timeframe after receipt of a Call-Off.</i>				<i>Within <b>seven (7) calendar days</b> upon issuance of Call-off .</i>
<i>Remarks</i>				<i>Please refer to the Terms and Conditions</i>
<b><i>Sgd.</i></b> <b><i>MARIA BERNADETTE P. IDJAO, MMPA</i></b>		<b><i>Chief Administrative Officer</i></b>		<b><i>Property and Supply Division</i></b>
<b><i>SIGNATURE OVER PRINTED NAME</i></b>		<b><i>POSITION</i></b>		<b><i>DEPARTMENT/DIVISION</i></b>

## ***Section VII. Technical Specifications***

### **Notes for Preparing the Technical Specifications**

A set of precise and clear specifications is a prerequisite for Bidders to respond realistically and competitively to the requirements of the Procuring Entity without qualifying their Bids. In the context of Competitive Bidding, the specifications (*e.g.* production/delivery schedule, manpower requirements, and after-sales service/parts, descriptions of the lots or items) must be prepared to permit the widest possible competition and, at the same time, present a clear statement of the required standards of workmanship, materials, and performance of the goods and services to be procured. Only if this is done will the objectives of transparency, equity, efficiency, fairness, and economy in procurement be realized, responsiveness of bids be ensured, and the subsequent task of bid evaluation and post-qualification facilitated. The specifications should require that all items, materials and accessories to be included or incorporated in the goods be new, unused, and of the most recent or current models, and that they include or incorporate all recent improvements in design and materials unless otherwise provided in the Contract.

Samples of specifications from previous similar procurements are useful in this respect. The use of metric units is encouraged. Depending on the complexity of the goods and the repetitiveness of the type of procurement, it may be advantageous to standardize the General Technical Specifications and incorporate them in a separate subsection. The General Technical Specifications should cover all classes of workmanship, materials, and equipment commonly involved in manufacturing similar goods. Deletions or addenda should then adapt the General Technical Specifications to the particular procurement.

Care must be taken in drafting specifications to ensure that they are not restrictive. In the specification of standards for equipment, materials, and workmanship, recognized Philippine and international standards should be used as much as possible. Where other particular standards are used, whether national standards or other standards, the specifications should state that equipment, materials, and workmanship that meet other authoritative standards, and which ensure at least a substantially equal quality than the standards mentioned, will also be acceptable. The following clause may be inserted in the Special Conditions of Contract or the Technical Specifications.

#### **Sample Clause: Equivalency of Standards and Codes**

Wherever reference is made in the Technical Specifications to specific standards and codes to be met by the goods and materials to be furnished or tested, the provisions of the latest edition or revision of the relevant standards and codes shall apply, unless otherwise expressly stated in the Contract. Where such standards and codes are national or relate to a particular country or region, other authoritative standards that ensure substantial equivalence to the standards and codes specified will be acceptable.

Reference to brand name and catalogue number should be avoided as far as possible; where unavoidable they should always be followed by the words “*or at least equivalent.*” References to brand names cannot be used when the funding source is the GOP.

Where appropriate, drawings, including site plans as required, may be furnished by the *University of the Philippines Manila – Philippine General Hospital* with the Bidding Documents. Similarly, the Supplier may be requested to during contract execution.

Bidders are also required, as part of the technical specifications, to complete their statement of compliance demonstrating how the items comply with the specification.



## Technical Specifications

Item	Specification	Statement of Compliance
		<i>[Bidders must state here either “Comply” or “Not Comply” against each of the individual parameters of each Specification stating the corresponding performance parameter of the equipment offered. Statements of “Comply” or “Not Comply” must be supported by evidence in a Bidders Bid and cross-referenced to that evidence. Evidence shall be in the form of manufacturer’s un-amended sales literature, unconditional statements of specification and compliance issued by the manufacturer, samples, independent test data etc., as appropriate. A statement that is not supported by evidence or is subsequently found to be contradicted by the evidence presented will render the Bid under evaluation liable for rejection. A statement either in the Bidder’s statement of compliance or the supporting evidence that is found to be false either during Bid evaluation, post-qualification or the execution of the Contract may be regarded as fraudulent and render the Bidder or supplier liable for prosecution subject to the applicable laws and issuances.]</i>

*[Use this form for Framework Agreement:]*

# Technical Specifications

<b>TECHNICAL SPECIFICATIONS</b>			
<b>Item No.</b>	<b>Description</b>	<b>Quantity</b>	<b>Statement of Compliance</b>
			<p><i>[Bidders must state here either “Comply” or “Not Comply” against each of the individual parameters of each Specification stating the corresponding performance parameter of the equipment offered. Statements of “Comply” or “Not Comply” must be supported by evidence in a Bidders Bid and cross-referenced to that evidence. Evidence shall be in the form of manufacturer’s un-amended sales literature, unconditional statements of specification and compliance issued by the manufacturer, samples, independent test data etc., as appropriate. A statement that is not supported by evidence or is subsequently found to be contradicted by the evidence presented will render the Bid under evaluation liable for rejection. A statement either in the Bidder's statement of compliance or the supporting evidence that is found to be false either during Bid evaluation, post-qualification or the execution of the Contract may be regarded as fraudulent and render the Bidder or supplier liable for prosecution.]</i></p>

<b>TECHNICAL SPECIFICATIONS</b>			
<b>Item No.</b>	<b>Description</b>	<b>Quantity</b>	<b>Statement of Compliance (Comply / Did not Comply)</b>
1	Acetylcysteine 200mg/mL, 25mL vial/bottle (IV infusion)	80	
2	Aciclovir 25mg/mL, 10mL vial (IV infusion)	2,400	
3	Albumin Human 20%, 50mL bottle (IV, IV infusion)	1,900	
4	Adenosine 3 mg/mL, 2 mL vial (IV)	32	
5	Amikacin sulfate 125mg/mL, 2mL ampule/vial (IM, IV)	1,240	
6	Amikacin sulfate 250mg/mL, 2mL ampule/vial (IM, IV)	1,200	
7	Aminophylline (theophylline ethylenediamine) 25 mg/mL, 10 mL ampul (IV)	2	
8	Amiodarone hydrochloride 50 mg/mL, 3 mL ampul (IV)	971	
9	Amphotericin B non lipid complex 50mg lyophilized powder, vial (IV infusion)	30	
10	Amphotericin B Lipid Complex (as cholesteryl complex, colloidal dispersion) 50 mg vial (IV infusion)	30	
11	Ampicillin + Sulbactam 1000 mg ampicillin + 500 mg sulbactam (IM, IV) (as sodium salt) per vial	5,000	
12	Ampicillin + Sulbactam 500 mg ampicillin + 250 mg sulbactam (IM, IV) (as sodium salt) per vial	3,120	
13	Ampicillin sodium 250mg vial (IM, IV)	2,340	
14	Ampicillin sodium 500mg vial (IM, IV)	2,250	
15	Asparaginase lyophilized powder, 10,000 IU vial (IV)	20	
16	Atracurium besilate 10mg/mL, 2.5mL ampule (IV)	110	
17	Atropine sulfate 1mg/mL, 1 mL ampul (IM, IV, SC)	585	
18	Azithromycin 500 mg powder, vial (IV infusion) (as base*/as dihydrate)	480	
19	Aztreonam 1g powder for injection (IV, IV Infusion)	1,000	

20	Beractant 25 mg/ml suspension, 8mL Intratracheal administration vial	4	
21	Beractant 25 mg/mL suspension, 4 mL Intratracheal administration vial	2	
22	Bleomycin sulfate powder, 15 IU ampul/vial (IM,IV)	2	
23	Bupivacaine Hydrochloride 0.5% 4 mL ampul (spinal) with 8% dextrose	100	
24	Bupivacaine Hydrochloride 0.5%, 10mL ampul/vial (local infiltration)	70	
25	Butorphanol tartrate 2 mg/mL, 1 mL ampul/vial (IM, IV)	5	
26	Calcium folinate (leucovorin Ca) 10mg/mL, 5mL ampule/vial (IM, IV)	1,200	
27	Calcium Gluconate 10%, 10 mL ampul/vial (IV)	4,820	
28	Carbetocin 100 mcg/mL, 1 mL ampule/vial, solution for Injection (IV)	30	
29	Carboprost 125 mcg/0.5 mL solution for injection, 0.5 mL ampul/vial	150	
30	Carboprost 250 mcg/mL solution for injection, 1 mL ampule/vial	40	
31	Cefazolin sodium 1gm vial (IM, IV)	6,010	
32	Cefepime Hydrochloride 1gm vial (IM, IV)	200	
33	Cefepime Hydrochloride 2gms vial (IM, IV)	1,440	
34	Cefotaxime sodium 500 mg vial + 2 mL diluent (IM, IV)	120	
35	Cefoxitin sodium 1gm vial (IM, IV)	36,640	
36	Ceftazidime pentahydrate 1gm vial (IM, IV)	8,000	
37	Ceftriaxone disodium/sodium 1gm vial + 10mL diluent (IV)	12,454	
38	Cefuroxime sodium 250mg vial (IM, IV)	50	
39	Cefuroxime sodium 750mg vial (IM, IV)	8,510	
40	Ciprofloxacin lactate 2mg/mL, 100mL vial (IV infusion)	1,030	
41	Clindamycin phosphate 150mg/mL, 2mL ampule/vial (IM, IV)	1,560	

42	Clindamycin phosphate 150mg/mL, 4mL ampule (IM, IV)	2,840	
43	Clonidine hydrochloride 150mcg/mL, 1mL ampule (IV)	15	
44	Colistin 2,000,000 IU lyophilized powder for injection (IV infusion)	200	
45	Cytarabine 100 mg/mL solution for injection, 1 mL	10	
46	Cytarabine 100 mg/mL solution for injection, 5 mL	2	
47	Cytarabine 100 mg/mL solution for injection, 10 mL	2	
48	Dactinomycin powder, 500 micrograms vial (IV)	10	
49	Deferoxamine mesilate powder, 500 mg vial (IM, IV infusion, SC)	203	
50	Dexamethasone sodium phosphate 4 mg/mL, 2 mL ampul/vial (IM, IV)	4,650	
51	Dexamethasone sodium phosphate 5mg/mL, 1mL ampule (IM, IV)	10,000	
52	Diazepam 5 mg/mL, 2 mL ampul (IM, IV) (With PDEA Permit)	220	
53	Digoxin 250 micrograms/mL, 2 mL ampul (IM, IV)	55	
54	Diphenhydramine Hydrochloride 50 mg/mL, 1 mL ampul (IM, IV)	4,575	
55	Dobutamine Hydrochloride 50mg/mL, 5ml ampule (IV infusion)	531	
56	Dopamine Hydrochloride 40mg/mL 5mL vial/ampule (IV)	570	
57	Doxorubicin Hydrochloride powder, 10mg vial or 2mg/mL, 5mL vial (IV)	20	
58	Doxorubicin Hydrochloride powder, 50mg vial or 2mg/mL, 25mL vial (IV)	20	
59	Enoxaparin sodium 100mg/mL, 0.2mL pre-filled syringe (SC)	8	
60	Enoxaparin sodium 100mg/mL, 0.4mL pre-filled syringe (SC)	10,070	
61	Enoxaparin sodium 100mg/mL, 0.6mL pre-filled syringe (SC)	2,545	

62	Epinephrine Hydrochloride 1mg/mL, 1mL ampule (IV, IM, SC)	3,295	
63	Epoetin alfa (recombinant human erythropoietin) 10,000 IU/mL, pre-filled syringe (IV, SC)	300	
64	Epoetin alfa (recombinant human erythropoietin) 4000 IU/0.4 mL, pre-filled syringe (IV, SC)	7,200	
65	Epoetin alfa (recombinant human erythropoietin) 2000 IU/0.5 mL, pre-filled syringe (IV, SC)	4	
66	Epoetin Beta (recombinant erythropoietin) 2000 IU/0.3 mL, pre-filled syringe with needle (IV, SC)	2	
67	Epoetin Beta (recombinant erythropoietin) 5000 IU/0.3 mL, pre-filled syringe with needle (IV, SC)	2,450	
68	Ertapenem sodium 1gm powder vial (IM/IV)	500	
69	Esmolol Hydrochloride 10mg/mL, 10mL vial (IV)	24	
70	Famotidine 20 mg powder/lyophilized powder for injection, ampule/vial (IV)	120	
71	Fentanyl citrate 50mcg/mL, 2mL amp (IV) (With PDEA Permit)	20,170	
72	Filgrastim 300 micrograms/1.2 mL, vial (IV, SC) or 300 micrograms/mL, vial (IV, SC)	19,800	
73	Fluconazole 2mg/mL, 100mL vial (IV infusion)	960	
74	Fluphenazine (as decanoate) 25mg/mL, 1mL ampule (IM)	15	
75	Fluorouracil 50 mg/mL, 10 mL ampul/vial (IV, IV infusion)	12	
76	Fondaparinux sodium 2.5 mg/0.5 mL solution (IV, SC)	10	
77	Furosemide 10 mg/mL, 2 mL ampul (IM, IV)	20,230	
78	Ganciclovir sodium 500 mg vial (IV infusion)	14	
79	Gemcitabine Hydrochloride 1gm vial (IV infusion)	2	
80	Gemcitabine Hydrochloride 200mg vial (IV infusion)	2	
81	Gentamicin sulfate 40mg/mL, 2mL ampule/vial (IM, IV)	730	
82	Glucose (dextrose) 50%, 50mL vial (IV)	6,000	

83	Glyceryl trinitrate (nitroglycerin) 1mg/mL, 10mL ampule (IV infusion)	50	
84	Haloperidol 5 mg/mL, 1 mL ampul (IM)	20	
85	Heparin sodium unfractionated 1,000 iu/mL, 5mL vial (IV infusion, SC) (bovine origin)	740	
86	Heparin sodium unfractionated 5000 IU/mL, 5 mL vial (IV infusion, SC) (bovine origin)	580	
87	Human recombinant tissue type plasminogen activator (alteplase) 50 mg powder for I.V. infusion	4	
88	Hydralazine Hydrochloride 20 mg/mL, 1 mL ampul (IM, IV)	26	
89	Hydrocortisone sodium succinate 50mg/mL, 2mL vial or 100mg powder vial (IV)	7,350	
90	Hydrocortisone sodium succinate 125 mg/mL, 2 mL vial (IV) or 250 mg powder vial (IV)	328	
91	Hyoscine-n-butylbromide 20mg/mL, 1mL ampule (IM, IV, SC)	960	
92	Ifosfamide powder, 2gms vial (IV infusion)	2	
93	Ifosfamide powder, 1g vial (IV infusion)	2	
94	Insulin, regular( recombinant DNA human) 100 IU/mL, 10mL vial (SC, IV/IM)	770	
95	Insulin, Biphasic Isophane Human 70/30 (recombinant DNA) 70% isophane suspension + 30% soluble insulin in 100 IU/mL, 10 mL vial (SC)	1,440	
96	Isophane Insulin Human (recombinant DNA) 100 IU/mL, 10 mL vial (SC)	540	
97	Isosorbide dinitrate 1mg/ml, 10mL ampule (IV)	320	
98	Iron sucrose 20mg/mL, 5mL ampule (IV, IV infusion)	820	
99	Isoxsuprine hydrochloride 5 mg/mL, 2 mL ampul (IM, IV infusion)	20	
100	Ketamine hydrochloride 50 mg/mL, 10 mL vial (IM, IV) (With PDEA Permit)	10	
101	Ketorolac tromethamol 30 mg/mL, 1 mL ampul (IM, IV)	10,900	
102	Leuprorelina (as acetate) powder, 3.75mg single dose with syringe (IM, SC)	70	

103	Levetiracetam 500 mg/5 mL (100 mg/mL) concentrate solution for IV infusion, 5 mL vial	1,500	
104	Levofloxacin 5 mg/mL solution for IV infusion, 100mL vial	1,540	
105	Lidocaine Hydrochloride 2% (20 mg/mL), 2 mL ampul/vial (IM/IV)	720	
106	Lidocaine Hydrochloride 2%, 5mL ampule/vial (IM/IV)	4,030	
107	Lidocaine Hydrochloride 2%, 50mL ampule/vial (IM, IV)	6	
108	Lidocaine Hydrochloride 2%, 1.8 mL carpule (with epinephrine) (local infiltration)	2	
109	Linezolid 2 mg/mL (600 mg/300 mL), solution for infusion (IV)	300	
110	Magnesium sulfate heptahydrate 250mg/mL, 20mL vial (IV)	3,060	
111	Meropenem trihydrate 1g powder vial (IV)	38,684	
112	Meropenem trihydrate 500mg powder vial (IV)	33,600	
113	Mesna (sodium-2mercapto ethanesulphonate) 100mg/mL, 4mL ampule (IV)	1,400	
114	Methotrexate 25 mg/mL, 2 mL ampul/vial (IM, IV, Intrathecal) (as base)	100	
115	Methylergometrine (methylergonovine) (as hydrogen maleate or maleate) 200 micrograms/mL, 1 mL ampul (IM, IV)	92	
116	Methylprednisolone 40 mg in single dose vial, solution for injection (IV, IM) (as sodium succinate)	20	
117	Methylprednisolone lyophilized powder, 500 mg vial (IM, IV) (as sodium succinate)	240	
118	Metoclopramide 5mg/mL, 2mL ampule (As Base and As Hydrochloride) (IM/IV)	9,870	
119	Metronidazole 5 mg/mL, 100 mL vial (IV infusion)	3,800	
120	Midazolam 1mg/mL, 5mL ampule or 5mg/mL, 1mL ampule (IM, IV) (With PDEA Permit)	4,700	
121	Midazolam 5mg/mL, 3mL ampule (IM, IV) (With PDEA Permit)	11,575	



122	Milrinone 10mg/ml, 10ml ampule (IV) (With Compassionate Special Permit)	500	
123	Morphine Sulfate 10 mg/mL, 1 mL ampul (IM, IV, SC) or 16 mg/mL, 1 mL ampul (IM, IV) (With PDEA Permit)	920	
124	Nalbuphine Hydrochloride 10 mg/mL, 1 mL ampul (IM, IV, SC) (With PDEA Permit)	416	
125	Naloxone hydrochloride 400 micrograms/mL, 1 mL ampul (IM, IV, SC)	5	
126	Neostigmine 500 mcg/mL solution for injection (IM/IV/SC), 1 mL ampule	60	
127	Nicardipine Hydrochloride 1mg/mL, 2mL ampule (IV)	60	
128	Nicardipine Hydrochloride 1mg/mL, 10mL ampule (IV)	31,142	
129	Norepinephrine bitartrate 1mg/mL, 2mL ampule (IV infusion)	5,000	
130	Norepinephrine bitartrate 1mg/mL, 4mL ampule (IV infusion)	9,630	
131	Octreotide acetate 100 micrograms/mL ampul (IV infusion)	800	
132	Omeprazole powder, 40 mg vial + 10 mL solvent ampul/vial (IV)	17,460	
133	Ondansetron 2mg/mL, 2mL ampule (IM, IV)	4,525	
134	Ondansetron 2mg/mL, 4mL ampule (IM, IV)	5,000	
135	Oxacillin sodium 500mg vial (IM, IV)	9,610	
136	Oxytocin (synthetic) 10 IU/mL, 1 mL ampul (IM, IV)	544	
137	Paracetamol 150mg/mL, 2mL ampule solution for injection (IM, IV)	75,550	
138	Paracetamol 10 mg/mL, 50 mL vial solution for infusion (IV)	1,000	
139	Paracetamol 10 mg/mL, 100 mL vial solution for infusion (IV)	1,200	
140	Penicillin G benzathine (benzathine benzylpenicillin) 1,200,000 units vial (MR) (IM)	85	
141	Penicillin G crystalline (benzylpenicillin) sodium 1,000,000 units vial (IM, IV)	30	

142	Penicillin G crystalline (benzylpenicillin) sodium 5,000,000 units vial (IM, IV)	10	
143	Pethidine (meperidine) (as hydrochloride) 50 mg/mL, 2 mL ampul (IM, IV, SC) (With PDEA Permit)	10	
144	Phenylephrine hydrochloride 10mg/1mL vial (With Compassionate Special Permit) (IV/IV Infusion)	2	
145	Phenytoin sodium 50mg/mL, 2mL ampule (IV)	20	
146	Phytomenadione (phytonadione, vitamin K1) 10mg/mL, 1mL ampul (IM, IV, SC) (as mixed micelle)	5,100	
147	Piperacillin + Tazobactam (as sodium salt) 2 g piperacillin + 250 mg tazobactam per vial (IV infusion)	37,464	
148	Piperacillin + Tazobactam (as sodium salt) 4 g piperacillin + 500 mg tazobactam per vial (IV infusion)	73,087	
149	Polymyxin B sulfate 500,000 Units powder for solution for injection (Intrathecal/IM/IV), 5 mL vial	1,500	
150	Potassium chloride 2meq/mL, 20mL vial (IV infusion)	3,890	
151	Propofol 10mg/mL, 20mL ampule/vial (IV)	150	
152	Protamine sulfate 10mg/mL, 5mL ampule (IV) (With Compassionate Special Permit)	2	
153	Ranitidine hydrochloride 25 mg/mL, 2 mL ampul/vial (IM, IV, IV infusion)	870	
154	Rocuronium bromide 10 mg/mL, 5 mL ampul/vial (IV)	10	
155	Sodium Bicarbonate 1 mEq/mL, 20 mL ampul/vial (adult) (IV infusion)	7,200	
156	Sodium bicarbonate 1mEq/mL, 50mL ampul/vial (adult) (IV infusion)	4,012	
157	Sodium Chloride 2.5mEq/mL, 20mL vial	2,415	
158	Sodium Chloride 0.9% 2mL ampul	600	
159	Sodium Chloride 0.9% 20mL ampul	60	
160	Somatostatin 250mcg ampule/vial (IV, IV infusion)	45	
161	Somatostatin 3mg ampule/vial (IV, IV infusion)	300	

162	Streptokinase powder, 1,500,000 IU vial (IV infusion)	27	
163	Streptomycin sulfate 1 g vial (IM)	17	
164	Sugammadex 100 mg/mL solution for injection (IV), 2 mL vial	12	
165	Suxamethonium (succinylcholine) chloride 20 mg/mL, 10 mL vial (IV)	18	
166	Terbutaline sulfate 500mcg/mL, 1mL ampule (IM, IV, SC)	45	
167	Tinzaparin (as sodium) 10,000 anti-Xa IU/mL, 0.45 mL pre-filled syringe (SC)	10	
168	Tramadol Hydrochloride 50mg/mL, 1mL ampule (IM, IV, SC)	10,090	
169	Tramadol Hydrochloride 50mg/mL, 2mL ampule (IM, IV, SC)	5,100	
170	Tranexamic acid 100mg/mL, 5mL ampule (IM, IV)	9,940	
171	Vancomycin Hydrochloride 500mg vial (IV)	34,170	
172	Vasopressin 20 IU/mL (IM, IV)	960	
173	Verapamil Hydrochloride 2.5 mg/mL, 2 mL ampul (IV)	20	
174	Vinblastine sulfate 1 mg/mL, 10 mL vial (IV)	2	
175	Vincristine sulfate 1 mg/mL, 1 mL vial (IV)	250	
176	Vincristine sulfate 1 mg/mL, 2 mL vial (IV)	250	
177	Vitamin B1 B6 B12 100 mg B1 + 100 mg B6 + 1 mg B12 per 3 mL ampul (IV)	32	
178	Voriconazole 200mg lyophilized powder for solution for IV infusion, 30mLVial	20	
<b>TOTAL APPROVED BUDGET FOR THE CONTRACT:</b>			<b><i>PhP310,777,412.77</i></b>
<b><i>TERMS AND CONDITIONS</i></b>			
1. Indicate the <b>brand and packing of the item/s</b> offered.			
2. The brand offered must be <b>at least five (5) years commercially available in the market from date of opening of bids</b> . Proof of this shall be the initial Certificate of Product Registration (CPR) issued by the Food and Drug Administration (FDA).			

3. <b>Submit the following documents, submission should be per product, with tab and per item number. <u>Two (2) copies for the Valid Certificate of Product Registration and Certificate of Analysis (COA).</u></b>	
<b>3.1. Memorandum of Agreement (MOA) and Certificate of exclusive/authorized distributorship between the manufacturer and distributor.</b> Distributors/suppliers must have certification from their principals that they are the exclusive distributor of the drug products authorized to submit tender for the product on behalf of the principal and that all commitments made by them shall be honored by the principal in case of termination of distributorship agreement.	
<b>3.2. Valid Certificate of Product Registration (CPR)</b> issued by the Food and Drug Administration (FDA). <ul style="list-style-type: none"> <li><b>The name of the respective distributor should appear in the submitted CPR of the drug.</b></li> </ul> <p><i>Note: CPRs that will expire within three (3) months from the date of opening of bids should present the Official Receipt of renewal of application with the Document Tracking log for the CPR from the FDA.</i></p>	
<b>3.3. Certificate of Analysis (COA)</b> for the products offered (batch to be delivered if awarded) duly issued by an FDA accredited laboratory (local) and should contain information indicated in monograph of the drug. Sample analyzed must not be expired during the time of bidding. The result of assay submitted must be in the specific brand and should be in the exact dosage formulation of the drug being bidded. In cases where local laboratories are unavailable to perform drug assays, assays done abroad is accepted. The local COA is preferred and given more weight in the evaluation and awarding process.	
<b>3.4. A notarized certificate</b> that it is the innovator drug (if applicable).	
<b>3.5. Certificate of Current Good Manufacturing Practice (CGMP).</b>	
<b>3.6. Valid License to Operate (LTO).</b>	
<b>3.7. A notarized certificate that the offered brand has not been subject to product complaint/product recall</b> for the past three (3) years.	
<b>3.8. Certificate of Acceptance</b> from at least three (3) major hospital issued within the year and should be supported with Sales Invoice ( <i>for new item/brand offered only</i> ).	

3.9.A <b>notarized certificate</b> that there are sufficient stocks for the offered item/s for one (1) year.	
4. The offered drug must conform to the latest Philippine Food and Drug Administration (FDA) Administrative Order <b>governing the generic labeling and packaging requirements.</b>	
<b>4.1 For all tablets and capsules</b>	
<b>4.1.1 All tablets/capsules should be in foil or blister pack. A picture of the blister pack (front and back) should be submitted.</b>	
4.1.2 Each individual flap in the tablet or capsule blister pack should be labeled with the generic name and brand.	
4.1.3 Dosage form and strength of the Active Pharmaceutical Ingredients (API) should appear on each unit or every 2 units for products with multiple APIs.	
4.1.4 Name of drug, lot or batch number and expiry date must appear on every standard blister pack/foil strip and on the container or inner packing. However, if the product is not restricted for dispensing in quantities less than the standard blister pack or foil strip, the batch or lot number and expiry date should appear on each unit.	
4.1.5. Inner label must be the same as the outer label.	
4.1.6 A complete drug literature/product insert must accompany the product.	
5. The following must be complied with specific for <b>cytotoxic injectable drugs.</b>	
5.1.For cytotoxic injectable drugs, winning bidders are required to <i>provide Material Safety Data Sheet (MSDS) and to submit Drug Profile</i> to the Pharmacy Department per company under the first Purchase Order.	
5.2. Winning bidders for cytotoxic injectable drugs are required to <b>provide at least three (3) spill kits</b> per company under the first Purchase Order.	

6. The brand offered on all antibiotics must have stability that is equivalent to that of the innovator product or better.	
7. <b>New brands offered</b> shall be subject to further evaluation and shall require the following:	
7.1. Validation of the submitted Certificate of Acceptance from at least three (3) major hospitals	
7.2. Justification from end-user/s to validate the acceptance of the good/s offered (to be facilitated by PGH-PSD).	
8. <b>For the supply and delivery of awarded drugs and medicines.</b>	
8.1 Delivery of the goods is required as stated in the request of the end-user, commencing on the 3rd working day of notification through confirmed fax/email that the approved Call-off/ Notice to Supplier (NTS) is already available for pick up.	
8.2 Delivery schedule (whichever is applicable): 8.1.1 within seven (7) calendar days; 8.1.2 as may be called for; 8.1.3 staggered delivery within three (3) months * 50% of the total quantity within seven (7) calendar days and 25% each for the succeeding months <i>Note: The end-user has the right to adjust the quantity to be delivered depending on the actual need of the hospital</i>	
8.3 Deliveries shall have at least two (2) years expiration date.	
8.4 Delivery of goods <b>with product complaint shall be put on hold</b> until receipt of the final decision of the PGH management whether to proceed with the acceptance or to cancel/return the items	
8.5 Delivered <b>items found to be non-formulary at any given time shall be returned</b> to the company and a credit memo shall be issued.	
8.6 Stocks delivered <b>are subject to random sampling for testing</b> as to quality and conformity to label. <u>Testing fee at supplier's expense.</u>	

8.7 Stocks with lot #/batch different from the submitted Certificate of Analysis (COA) will be subjected to testing as to quality and conformity to label. <u>Testing fee at supplier's expense.</u>	
8.8 All items that had been pulled out for various reasons, a credit memo shall be issued by the Contractor within one (1) month, otherwise, a debit memo shall be processed by UP Manila - PGH and the amount will be deducted from any amount due to Supplier.	
8.9 It is understood that the Supplier is legally responsible to deliver all issued <b>CALL-OFF/s</b> (Purchase Order) and <b>failure to deliver the first Call-Off as scheduled shall mean automatic cancellation of the Call-Off and Notice to Execute Framework Agreement (NEFA)</b> . Purchase from other source for whatever means shall be effected immediately to provide the requirements of the hospital. Penalty to the defaulting contractor shall be charged accordingly.	
<b>9. Failure to comply with the submission of the required documents shall be ground for post-disqualification in accordance with RA 9184.</b>	
10. Compliance with RA 9184 and other applicable laws.	

I hereby certify to comply and deliver all the above requirements

\_\_\_\_\_  
Name of Company/ Bidder

\_\_\_\_\_  
Signature over Printed Name of Representative

\_\_\_\_\_  
Date

## ***Section VIII. Checklist of Technical and Financial Documents***

### **Notes on the Checklist of Technical and Financial Documents**

The prescribed documents in the checklist are mandatory to be submitted in the Bid, but shall be subject to the following:

- a. GPPB Resolution No. 09-2020 on the efficient procurement measures during a State of Calamity or other similar issuances that shall allow the use of alternate documents in lieu of the mandated requirements; or
- b. Any subsequent GPPB issuances adjusting the documentary requirements after the effectivity of the adoption of the PBDs.

The BAC shall be checking the submitted documents of each Bidder against this checklist to ascertain if they are all present, using a non-discretionary “pass/fail” criterion pursuant to Section 30 of the 2016 revised IRR of RA No. 9184.



# Checklist of Technical and Financial Documents

## I. TECHNICAL COMPONENT ENVELOPE

### *Class “A” Documents*

#### Legal Documents

- ☐ (a) Valid PhilGEPS Registration Certificate (Platinum Membership) (all pages);
- ☐ (b) Registration certificate from Securities and Exchange Commission (SEC), Department of Trade and Industry (DTI) for sole proprietorship, or Cooperative Development Authority (CDA) for cooperatives or its equivalent document,
- ☐ (c) Mayor’s or Business permit issued by the city or municipality where the principal place of business of the prospective bidder is located, or the equivalent document for Exclusive Economic Zones or Areas;
- ☐ (d) Tax clearance per E.O. No. 398, s. 2005, as finally reviewed and approved by the Bureau of Internal Revenue (BIR).
- ☐ (e) Notarized UP Questionnaire

#### Technical Documents

- ☐ (f) Statement of the prospective bidder of all its ongoing government and private contracts, including contracts awarded but not yet started, if any, whether similar or not similar in nature and complexity to the contract to be bid;
- ☐ (g) Statement of the bidder’s Single Largest Completed Contract (SLCC) similar to the contract to be bid, except under conditions provided for in Sections 23.4.1.3 and 23.4.2.4 of the 2016 revised IRR of RA No. 9184, within the relevant period as provided in the Bidding Documents;
- ☐ (h) Original copy of Bid Security. If in the form of a Surety Bond, submit also a certification issued by the Insurance Commission;  
**or**  
Original copy of Notarized Bid Securing Declaration;
- ☐ (i) Conformity with the Technical Specifications, which may include production/delivery schedule, manpower requirements, and/or after-sales/parts, if applicable;
- ☐ (j) Original duly signed Omnibus Sworn Statement (OSS);  
**and** if applicable, Original Notarized Secretary’s Certificate in case of a corporation, partnership, or cooperative; or Original Special Power of Attorney of all members of the joint venture giving full power and authority to its officer to sign the OSS and do acts to represent the Bidder.

#### Financial Documents

- ☐ (k) The Supplier’s audited financial statements, showing, among others, the Supplier’s total and current assets and liabilities, stamped “received” by the BIR or its duly accredited and authorized institutions, for the preceding calendar year which should not be earlier than two (2) years from the date of bid submission;
- ☐ (l) The prospective bidder’s computation of Net Financial Contracting Capacity (NFCC);  
**or**  
A committed Line of Credit from a Universal or Commercial Bank in lieu of its NFCC computation.

***Class “B” Documents***

- ☐ (m) If applicable, a duly signed joint venture agreement (JVA) in case the joint venture is already in existence;  
**or**  
duly notarized statements from all the potential joint venture partners stating that they will enter into and abide by the provisions of the JVA in the instance that the bid is successful.

***Other documentary requirements under RA No. 9184 (as applicable)***

- ☐ (n) *[For foreign bidders claiming by reason of their country’s extension of reciprocal rights to Filipinos]* Certification from the relevant government office of their country stating that Filipinos are allowed to participate in government procurement activities for the same item or product.
- ☐ (o) Certification from the DTI if the Bidder claims preference as a Domestic Bidder or Domestic Entity.

**25 FINANCIAL COMPONENT ENVELOPE**

- ☐ (a) Original of duly signed and accomplished Financial Bid Form;
- ☐ (b) Original of duly signed and accomplished Price Schedule(s); **and**
- ☐ (c) Original of duly signed and accomplished Price Schedule (Annex)

## Bid Form

---

Date: \_\_\_\_\_  
Project Reference No.: \_\_\_\_\_

### THE BIDS AND AWARDS COMMITTEE 1

UPM – Philippine General Hospital  
Taft Avenue, Manila

Gentlemen and/or Ladies:

Having examined the Philippine Bidding Documents (PBDs) including the Supplemental or Bid Bulletin Numbers *[insert numbers]*, the receipt of which is hereby duly acknowledged, we, the undersigned, offer to *[supply/deliver/perform]* *[description of the Goods]* in conformity with the said PBDs for the sum of *[total Bid amount in words and figures]* or the total calculated bid price, as evaluated and corrected for computational errors, and other bid modifications in accordance with the Price Schedules attached herewith and made part of this Bid. The total bid price includes the cost of all taxes, such as, but not limited to: *[specify the applicable taxes, e.g. (i) value added tax (VAT), (ii) income tax, (iii) local taxes, and (iv) other fiscal levies and duties]*, which are itemized herein or in the Price Schedules,

If our Bid is accepted, we undertake:

- a. to deliver the goods in accordance with the delivery schedule specified in the Schedule of Requirements of the Philippine Bidding Documents (PBDs);
- b. to provide a performance security in the form, amounts, and within the times prescribed in the PBDs;
- c. to abide by the Bid Validity Period specified in the PBDs and it shall remain binding upon us at any time before the expiration of that period.

*[Insert this paragraph if Foreign-Assisted Project with the Development Partner:*

Commissions or gratuities, if any, paid or to be paid by us to agents relating to this Bid, and to contract execution if we are awarded the contract, are listed below:

Name and address of agent	Amount and Purpose of Commission or gratuity
---------------------------	--

_____	_____
_____	_____
_____	_____

(if none, state “None”) ]

Until a formal Contract is prepared and executed, this Bid, together with your written acceptance thereof and your Notice of Award, shall be binding upon us.

We understand that you are not bound to accept the Lowest Calculated Bid or any Bid you may receive.

We certify/confirm that we comply with the eligibility requirements pursuant to the PBDs.

The undersigned is authorized to submit the bid on behalf of *[name of the bidder]* as evidenced by the attached *[state the written authority]*.

We acknowledge that failure to sign each and every page of this Bid Form, including the attached Schedule of Prices, shall be a ground for the rejection of our bid.

Name: \_\_\_\_\_

Legal capacity: \_\_\_\_\_

Signature: \_\_\_\_\_

Duly authorized to sign the Bid for and behalf of: \_\_\_\_\_

Date: \_\_\_\_\_

**Price Schedule for Goods Offered from Abroad**  
*[shall be submitted with the Bid if bidder is offering goods from Abroad]*

***For Goods Offered from Abroad***

Name of Bidder: \_\_\_\_\_ Project Reference No. \_\_\_\_\_ Page \_\_\_\_ of \_\_\_\_

1	2	3	4	5	6	7	8	9	10
Item	Description	Brand Name	Country of origin	Quantity	Unit price CIF port of entry (specify port) or CIP named place  (specify border point or place of destination)	Total CIF or CIP price per item  (col. 5 x 6)	Unit Price Delivered Duty Unpaid (DDU)	Unit price Delivered Duty Paid (DDP)	Total Price delivered DDP (col 5 x 9)

Name: \_\_\_\_\_

Legal Capacity: \_\_\_\_\_

Signature: \_\_\_\_\_

Duly authorized to sign the Bid for and behalf of: \_\_\_\_\_

**Price Schedule for Goods Offered from Within the Philippines**  
*[shall be submitted with the Bid if bidder is offering goods from within the Philippines]*

### For Goods Offered from Within the Philippines

Name of Bidder \_\_\_\_\_ Project Ref No. \_\_\_\_\_ Page \_\_\_ of \_\_\_

[illegible]

Name: \_\_\_\_\_

Legal Capacity: \_\_\_\_\_

Signature: \_\_\_\_\_

Duly authorized to sign the Bid for and behalf of: \_\_\_\_\_

## Contract Agreement

---

THIS AGREEMENT made the \_\_\_\_\_ day of \_\_\_\_\_ 20\_\_\_\_ between [name of PROCURING ENTITY] of the Philippines (hereinafter called “the Entity”) of the one part and [name of Supplier] of [city and country of Supplier] (hereinafter called “the Supplier”) of the other part;

WHEREAS, the Entity invited Bids for certain goods and ancillary services, particularly [brief description of goods and services] and has accepted a Bid by the Supplier for the supply of those goods and services in the sum of [*contract price in words and figures in specified currency*] (hereinafter called “the Contract Price”).

### NOW THIS AGREEMENT WITNESSETH AS FOLLOWS:

1. In this Agreement words and expressions shall have the same meanings as are respectively assigned to them in the Conditions of Contract referred to.
2. The following documents as required by the 2016 revised Implementing Rules and Regulations of Republic Act No. 9184 shall be deemed to form and be read and construed as integral part of this Agreement, *viz.*:
  - i. Philippine Bidding Documents (PBDs);
    - i. Schedule of Requirements;
    - ii. Technical Specifications;
    - iii. General and Special Conditions of Contract; and
    - iv. Supplemental or Bid Bulletins, if any
  - ii. Winning bidder’s bid, including the Eligibility requirements, Technical and Financial Proposals, and all other documents or statements submitted;  
  
Bid form, including all the documents/statements contained in the Bidder’s bidding envelopes, as annexes, and all other documents submitted (*e.g.*, Bidder’s response to request for clarifications on the bid), including corrections to the bid, if any, resulting from the Procuring Entity’s bid evaluation;
  - iii. Performance Security;
  - iv. Notice of Award of Contract; and the Bidder’s conforme thereto; and
  - v. Other contract documents that may be required by existing laws and/or the Procuring Entity concerned in the PBDs. **Winning bidder agrees that additional contract documents or information prescribed by the GPPB that are subsequently required for submission after the contract execution, such as the Notice to Proceed, Variation Orders, and Warranty Security, shall likewise form part of the Contract.**

3. In consideration for the sum of *[total contract price in words and figures]* or such other sums as may be ascertained, *[Named of the bidder]* agrees to *[state the object of the contract]* in accordance with his/her/its Bid.
4. The *[Name of the procuring entity]* agrees to pay the above-mentioned sum in accordance with the terms of the Bidding.

IN WITNESS whereof the parties hereto have caused this Agreement to be executed in accordance with the laws of the Republic of the Philippines on the day and year first above written.

<p><i>[Insert Name and Signature]</i></p> <p><i>[Insert Signatory's Legal Capacity]</i></p> <p><i>for:</i></p> <p><i>[Insert Procuring Entity]</i></p>	<p><i>[Insert Name and Signature]</i></p> <p><i>[Insert Signatory's Legal Capacity]</i></p> <p><i>for:</i></p> <p><i>[Insert Name of Supplier]</i></p>
--	--

#### **Acknowledgment**

*[Format shall be based on the latest Rules on Notarial Practice]*



## Omnibus Sworn Statement

---

REPUBLIC OF THE PHILIPPINES     )  
CITY/MUNICIPALITY OF \_\_\_\_\_ ) S.S.

### AFFIDAVIT

I, [Name of Affiant], of legal age, [Civil Status], [Nationality], and residing at [Address of Affiant], after having been duly sworn in accordance with law, do hereby depose and state that:

1. *[Select one, delete the other:]*

*[If a sole proprietorship:]* I am the sole proprietor or authorized representative of [Name of Bidder] with office address at [address of Bidder];

*[If a partnership, corporation, cooperative, or joint venture:]* I am the duly authorized and designated representative of [Name of Bidder] with office address at [address of Bidder];

2. *[Select one, delete the other:]*

*[If a sole proprietorship:]* As the owner and sole proprietor, or authorized representative of [Name of Bidder], I have full power and authority to do, execute and perform any and all acts necessary to participate, submit the bid, and to sign and execute the ensuing contract for [Name of the Project] of the [Name of the Procuring Entity], as shown in the attached duly notarized Special Power of Attorney;

*[If a partnership, corporation, cooperative, or joint venture:]* I am granted full power and authority to do, execute and perform any and all acts necessary to participate, submit the bid, and to sign and execute the ensuing contract for [Name of the Project] of the [Name of the Procuring Entity], as shown in the attached [state title of attached document showing proof of authorization (e.g., duly notarized Secretary's Certificate, Board/Partnership Resolution, or Special Power of Attorney, whichever is applicable)];

3. [Name of Bidder] is not "blacklisted" or barred from bidding by the Government of the Philippines or any of its agencies, offices, corporations, or Local Government Units, foreign government/foreign or international financing institution whose blacklisting rules have been recognized by the Government Procurement Policy Board, **by itself or by relation, membership, association, affiliation, or controlling interest with another blacklisted person or entity as defined and provided for in the Uniform Guidelines on Blacklisting;**

4. Each of the documents submitted in satisfaction of the bidding requirements is an authentic copy of the original, complete, and all statements and information provided therein are true and correct;

5. [Name of Bidder] is authorizing the Head of the Procuring Entity or its duly authorized

representative(s) to verify all the documents submitted;

6. *[Select one, delete the rest:]*

*[If a sole proprietorship:]* The owner or sole proprietor is not related to the Head of the Procuring Entity, members of the Bids and Awards Committee (BAC), the Technical Working Group, and the BAC Secretariat, the head of the Project Management Office or the end-user unit, and the project consultants by consanguinity or affinity up to the third civil degree;

*[If a partnership or cooperative:]* None of the officers and members of *[Name of Bidder]* is related to the Head of the Procuring Entity, members of the Bids and Awards Committee (BAC), the Technical Working Group, and the BAC Secretariat, the head of the Project Management Office or the end-user unit, and the project consultants by consanguinity or affinity up to the third civil degree;

*[If a corporation or joint venture:]* None of the officers, directors, and controlling stockholders of *[Name of Bidder]* is related to the Head of the Procuring Entity, members of the Bids and Awards Committee (BAC), the Technical Working Group, and the BAC Secretariat, the head of the Project Management Office or the end-user unit, and the project consultants by consanguinity or affinity up to the third civil degree;

7. *[Name of Bidder]* complies with existing labor laws and standards; and

8. *[Name of Bidder]* is aware of and has undertaken the responsibilities as a Bidder in compliance with the Philippine Bidding Documents, which includes:

- a. Carefully examining all of the Bidding Documents;
- b. Acknowledging all conditions, local or otherwise, affecting the implementation of the Contract;
- c. Making an estimate of the facilities available and needed for the contract to be bid, if any; and
- d. Inquiring or securing Supplemental/Bid Bulletin(s) issued for the *[Name of the Project]*.

9. *[Name of Bidder]* did not give or pay directly or indirectly, any commission, amount, fee, or any form of consideration, pecuniary or otherwise, to any person or official, personnel or representative of the government in relation to any procurement project or activity.

**10. In case advance payment was made or given, failure to perform or deliver any of the obligations and undertakings in the contract shall be sufficient grounds to constitute criminal liability for Swindling (Estafa) or the commission of fraud with unfaithfulness or abuse of confidence through misappropriating or converting any payment received by a person or entity under an obligation involving the duty to deliver certain goods or services, to the prejudice of the public and the government of the Philippines pursuant to Article 315 of Act No. 3815 s. 1930, as amended, or the Revised Penal Code.**

**IN WITNESS WHEREOF**, I have hereunto set my hand this \_\_\_\_ day of \_\_\_\_, 20\_\_ at \_\_\_\_\_, Philippines.

*[Insert NAME OF BIDDER OR ITS AUTHORIZED REPRESENTATIVE]*

*[Insert signatory's legal capacity]*

Affiant

**[Jurat]**

*[Format shall be based on the latest Rules on Notarial Practice]*

## Bank Guarantee Form for Advance Payment

---

### THE BIDS AND AWARDS COMMITTEE 1

UPM – Philippine General Hospital  
Taft Avenue, Manila

Name of Contract: \_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_

***under Project Reference No.***

Gentlemen and/or Ladies:

In accordance with the payment provision included in the Special Conditions of Contract, which amends Clause 2 of the General Conditions of Contract to provide for advance payment, *[name and address of Supplier]* (hereinafter called the “Supplier”) shall deposit with the PROCURING ENTITY a bank guarantee to guarantee its proper and faithful performance under the said Clause of the Contract in an amount of *[amount of guarantee in figures and words]*.

We, the *[bank or financial institution]*, as instructed by the Supplier, agree unconditionally and irrevocably to guarantee as primary obligator and not as surety merely, the payment to the PROCURING ENTITY on its first demand without whatsoever right of objection on our part and without its first claim to the Supplier, in the amount not exceeding *[amount of guarantee in figures and words]*.

We further agree that no change or addition to or other modification of the terms of the Contract to be performed there under or of any of the Contract documents which may be made between the PROCURING ENTITY and the Supplier, shall in any way release us from any liability under this guarantee, and we hereby waive notice of any such change, addition, or modification.

This guarantee shall remain valid and in full effect from the date of the advance payment received by the Supplier under the Contract until *[date]*.

Yours truly,

Signature and seal of the Guarantors

\_\_\_\_\_  
*[name of bank or financial institution]*

\_\_\_\_\_  
*[address]*

\_\_\_\_\_  
*[date]*

## Bid Securing Declaration Form

REPUBLIC OF THE PHILIPPINES)  
CITY OF \_\_\_\_\_) S.S.

X-----X

### BID SECURING DECLARATION Project Reference No.: \_\_\_\_\_

#### BIDS AND AWARDS COMMITTEE 1

UPM-Philippine General Hospital  
Taft Avenue, Manila

I/We, the undersigned, declare that:

1. I/We understand that, according to your conditions, bids must be supported by a Bid Security, which may be in the form of a Bid Securing Declaration.
2. I/We accept that: (a) I/we will be automatically disqualified from bidding for any procurement contract with any procuring entity for a period of two (2) years upon receipt of your Blacklisting Order; and, (b) I/we will pay the applicable fine provided under Section 6 of the Guidelines on the Use of Bid Securing Declaration, within fifteen (15) days from receipt of the written demand by the procuring entity for the commission of acts resulting to the enforcement of the bid securing declaration under Sections 23.1(b), 34.2, 40.1 and 69.1, except 69.1(f), of the IRR of RA No. 9184; without prejudice to other legal action the government may undertake.
3. I/We understand that this Bid Securing Declaration shall cease to be valid on the following circumstances:
  - a. Upon expiration of the bid validity period, or any extension thereof pursuant to your request;
  - b. I am/we are declared ineligible or post-disqualified upon receipt of your notice to such effect, and (i) I/we failed to timely file a request for reconsideration or (ii) I/we filed a waiver to avail of said right; and
  - c. I am/we are declared the bidder with the Lowest Calculated Responsive Bid, and I/we have furnished the performance security and signed the Contract.

IN WITNESS WHEREOF, I/We have hereunto set my/our hand/s this \_\_\_\_ day of [month]  
[year] at [place of execution].

[Insert NAME OF BIDDER OR ITS AUTHORIZED  
REPRESENTATIVE]  
[Insert signatory's legal capacity]  
Affiant

**[Jurat]**  
[Format shall be based on the latest Rules on Notarial Practice]

### NFCC Computation

Project Reference No.: \_\_\_\_\_

ABC: \_\_\_\_\_

**Kindly supply the required information in the spaces provided.**

Name of Bidder: \_\_\_\_\_

DETAILS	AMOUNT
Current Assets	
Minus	
Current Liabilities	
Difference of Current Assets and Current Liabilities	
Multiplied by	
K	15
Total (Product)	
Minus	
Total amount of the Value of Outstanding Contracts	
Total NFCC Computation	

\_\_\_\_\_  
[signature]

\_\_\_\_\_  
[in the capacity of]

Duly authorized to sign Bid for and on behalf of \_\_\_\_\_

Standard Form Number: SF-GOOD-17  
Revised on: May 24, 2004

University of the Philippines Manila/  
Philippine General Hospital

Project Reference No.  
Name of Project:

Location of Project:

## Joint Venture Agreement

KNOWN ALL BY THESE PRESENTS:

That this JOINT VENTURE AGREEMENT is entered into By and Between \_\_\_\_\_, of legal age, \_\_\_\_\_, owner/proprietor of \_\_\_\_\_  
(civil status)  
and a resident of \_\_\_\_\_.

-and-

\_\_\_\_\_, of legal age, \_\_\_\_\_,  
(civil status)  
owner/proprietor of \_\_\_\_\_ a resident of \_\_\_\_\_.

That both parties agree to join together their manpower, equipment, and what is need to facilitate the Joint Venture to participate in the Eligibility, Bidding and Undertaking of the here-under stated project to be conducted by the University of the Philippines Manila/Philippine General Hospital.

NAME OF PROJECT

CONTRACT AMOUNT

That both parties agree to jointly and severally liable for the entire assignment.

That both parties agree that \_\_\_\_\_ and/or \_\_\_\_\_ shall be the Official Representative of the Joint Venture, and is granted full power and authority to do, execute and perform any and all acts necessary and /or to represent the Joint Venture in the bidding as fully and effectively and the Joint Venture may do and if personally present with full power of substitution and revocation.

That this Venture Agreement shall remain in effect only for the above stated Projects until terminated by both parties.

Done this \_\_\_ day of \_\_\_\_\_, in the year of the Lord \_\_\_\_\_

\_\_\_\_\_  
(Name of Company)

\_\_\_\_\_  
(Address of the Company)

\_\_\_\_\_  
(Telephone & Fax of the Company)

\_\_\_\_\_  
(Website Address of the Company)

\_\_\_\_\_  
(e-Mail Address of the Company)

\_\_\_\_\_  
(Date of Issuance)

## Letter of Acceptance

This is to certify that \_\_\_\_\_ has satisfactorily delivered  
(Name of Bidder)

\_\_\_\_\_  
(Item Description)

under P.O. No/s. \_\_\_\_\_ with Sales Invoice No. \_\_\_\_\_ and accepted on  
\_\_\_\_\_. Said company has no more pending obligation with us regarding their  
delivery/ies.

\_\_\_\_\_  
(Signature over Printed Name)

\_\_\_\_\_  
(Position)

\_\_\_\_\_  
(Company Name)

University of the Philippines  
Diliman, Quezon City

**Questionnaire for Prospective Bidders**  
(additional requirement for eligibility)



1. Have you ever participated in any bidding in the University of the Philippines System?

YES	NO

If YES, fill up the table below. Use additional pages if necessary.

Constituent University/UP Campus	Name of the Project	Amount of Project	Duration Start/End (Dates)	Status (On-going/ Completed)

2. Has your company ever been suspended or blacklisted by the University of the Philippines System?

YES	NO

If YES, fill up the table below. Use additional pages if necessary.

Constituent University/UP Campus	Name of the Project	Reason for suspension/ blacklisting	Status (On-going/ Completed)

3. Has your company ever been suspended or blacklisted by any government agency or private company?

YES	NO

If YES, fill up the table below. Use additional pages if necessary.

Name of government agency/company	Name of the Project	Reason for suspension/blacklisting	Status (On-going/Completed)

4. Has there ever been any project of your company in the University of the Philippines that was terminated by Administration?

YES	NO	NA

If YES, fill up the table below. Use additional pages if necessary.

Constituent University/UP Campus	Name of the Project	Reason for suspension/blacklisting	Status (On-going/Completed)

5. Do you certify that all the documents submitted by your Company and personnel are authentic?

YES	NO

6. Is there any pending investigation and/or case filed against your Company or your personnel in any court or any similar institution in relation to any government contracts awarded to your company? In relation to practice of profession of any of your personnel?

YES	NO

If YES, fill up the table below. Use additional pages if necessary.

For Company

Case Filed	Where Filed	Date Filed	Status (On-going/ Completed)	Remarks

For Personnel

Case Filed	Where Filed	Date Filed	Status (On-going/ Completed)	Remarks

I hereby certify that all statements and information provided herein are complete, true and correct.

Name & Signature of Bidder : \_\_\_\_\_  
 Authorized Representative : \_\_\_\_\_  
 Official Designation : \_\_\_\_\_  
 Company : \_\_\_\_\_  
 Date : \_\_\_\_\_

#### ACKNOWLEDGEMENT

SUBSCRIBED AND SWORN TO before me this \_\_\_\_\_ day of \_\_\_\_\_, 20\_\_,  
 affiant exhibited to me his/her Community Tax Certificate No. \_\_\_\_\_  
 issued on \_\_\_\_\_ at \_\_\_\_\_, Philippines.

Notary Public  
Until 31 December 20\_\_  
PTR No.: \_\_\_\_\_  
Issued at: \_\_\_\_\_  
Issued on: \_\_\_\_\_

TIN: \_\_\_\_\_

Project Reference No.  
Name of Project:  
Location of Project:

## Statement of All On-Going Government and Private Contracts

### Including Contracts Awarded but Not Yet Started

BusinessName: \_\_\_\_\_  
BusinessAddress: \_\_\_\_\_

Name of Contract/ Project Cost	a. Owner's Name b. Address c. Telephone Nos.	Nature of Work	Bidder's Role		a. Date Awarded b. Date Started c. Date of Completion	% of accomplishment		Value of Outstanding Works/Undelivered Portion
			Description	%		Planned	Actual	
Government								
Private								

Note: This statement shall be supported with:  
1. Notice of Award and/or Contract  
2. Notice to Proceed issued by the owner

Total Cost

Submitted by : \_\_\_\_\_  
(Printed Name & Signature)

Designation : \_\_\_\_\_

Date : \_\_\_\_\_

Project Reference No.  
Name of Project:  
Location of Project:

## Statement of the Single Largest Completed Contract

Business Name: \_\_\_\_\_

Business Address: \_\_\_\_\_

Name of Contract	a. Owner's Name b. Address c. Telephone Nos.	Nature of Work	Bidder's Role		a. Amount at Award b. Amount at Completion c. Duration	a. Date Awarded b. Contract Effectivity c. Date Completed	
			Description	%			
Government							
Private							


Note: This statement shall be supported with:

1. Contract
2. Certificate of Completion
3. Certification of Acceptance

Submitted by : \_\_\_\_\_  
(Printed Name & Signature)

Designation : \_\_\_\_\_  
Date : \_\_\_\_\_

## Sample Diagram for Bid Packaging



# Sealing and Marking of Envelopes

**ALL folders / envelopes** shall be marked in accordance with Section 20.4 of the Instruction to Bidders in the Bidding Documents, which shall contain the following:

- Name of the contract to be bid in **CAPITAL LETTERS**;

-

## **SUPPLY & DELIVERY OF VARIOUS DRUGS AND MEDICINES – AMPULES AND VIALS RESALE FOR CY2023 (FRAMEWORK AGREEMENT)**

- Name and address of the prospective bidder in **CAPITAL LETTERS**;
- Be addressed to the Procuring Entity's BAC in accordance with ITB Clause 1.1;

**BIDS AND AWARDS COMMITTEE (BAC) 1  
UPM – PHILIPPINE GENERAL HOSPITAL  
TAFT AVENUE, MANILA**

- Bear the specific identification of this bidding process indicated in ITB Clause 1.2;

**Project Reference No.: BAC1-2022-11-0077-A**

Bear a warning “**DO NOT OPEN BEFORE...**” the date and time for the opening of bids, in accordance with ITB Clause 18

**The color of the folders and envelopes to be used is Violet/ Purple**